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Zusammenfassung
Zusammenfassung
Prima¨res Ziel dieser Doktorarbeit war die funktionelle Charakterisierung von Endoglin
im Transdifferenzierungsprozess von Hepatischen Sternzellen (HSC) zu Myofibroblas-
ten a¨hnlichen Zellen (MFB). Die Transdifferenzierung von HSC zu MFB spielt eine
wichtige Rolle in Wundheilungsprozessen der Leber sowie bei der Entstehung der
Leberfibrose. Da Endoglin ein TGF-β Typ III Rezeptor ist und TGF-β1 wiederum das
Schlu¨sselzytokin bei der Initiierung und Aufrechterhaltung der Transdifferenzierung
darstellt, dra¨ngte sich die Frage auf, ob Endoglin einen Einfluss auf die Transdifferen-
zierung von HSC und somit auch einen Einfluss auf die Leberfibrose hat.
Um dieser Fragestellung nachzugehen, wurde eine fu¨r dieses Labor neue Methode
etabliert. Bei dieser Methode handelt es sich um RNA Interferenz, mit der es mo¨glich
war, die Expression von Endoglin in Hepatischen Sternzellen durch siRNA Oligonukleo-
tide sehr effizient zu inhibieren. Die Endoglin defizienten Zellen sowie die zugeho¨rigen
Kontrollzellen wurden anschließend hinsichtlich verschiedener Aspekte der Transdif-
ferenzierung analysiert. Dabei konnte gezeigt werden, dass Endoglin defiziente HSC
eine inhibierte Transdifferenzierung aufweisen. Dieses spiegelte sich in einer vermin-
derten Anreicherung von ECM Komponenten, einem vera¨nderten Aufbau des Zyto-
skeletts und einer verminderten Proliferation wider. Um weitere Mediatoren bestim-
men zu ko¨nnen, die durch eine vera¨nderte Expression den Pha¨notypen der Endoglin
defizienten HSC mitbestimmen, wurde ein cDNA Microarray angefertigt. Aus diesem
Array gingen u.a. α2-Macroglobulin und ALK1 hervor, die aufgrund ihrer bekann-
ten Funktionen mo¨glicherweise eine wichtige Rolle bei der Manifestierung des Pha¨no-
typens einnehmen. Zuletzt wurde der Einfluss von Endoglin auf den TGF-β und den
BMP-7 Signalweg untersucht, denn sowohl TGF-β1 als auch BMP-7 werden von En-
doglin gebunden und nehmen eine wichtige Funktion in der Entstehung der Leberfi-
brose ein. Stimuliert wurde sowohl mit TGF-β1 als auch mit BMP-7. Als Readout-System
diente der Western Blot und der Reporter-Gen-Assay.
Das Fazit dieser Arbeit ist: Endoglin spielt eine wichtige Rolle in der in vitro Trans-
differenzierung von HSC zu MFB. Ein knock down von Endoglin fu¨hrt zur Inhibierung
der Transdifferenzierung und zu zahlreichen pha¨notypischen Vera¨nderungen. Auf-
grund dieser Feststellung ist zu vermuten, dass Endoglin ebenfalls eine wichtige Rolle
bei der Entstehung der Leberfibrose einnimmt.
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Summary
Summary
The main purpose of this doctoral thesis was the functional characterization of endoglin
in hepatic stellate cells (HSC). This characterization was performed particularly with
regard to the impact and the function of endoglin in the transdifferentiation process of
HSC into myofibroblast-like cells (MFB). Transdifferentiation of HSC into MFB plays a
crucial role in the wound healing process of the liver and is, thus, linked to the devel-
opment of fibrosis. Endoglin functions as a TGF-β receptor and TGF-β, on the other
hand, is a key regulator that initiates and perpetuates the transdifferentiation process.
This raises the questions whether endoglin has any impact on the transdifferentiation
of HSC and whether endoglin is involved in the process of liver fibrogenesis.
To investigate these questions, RNAi was used for the first time in this laboratory in
order to silence endoglin. By transfecting HSC with siRNA oligonucleotides endoglin
was down-regulated very efficiently. Subsequently, endoglin lacking HSC were ana-
lyzed and compared with the control cells providing a first insight into the function of
endoglin in HSC. This analysis revealed an inhibition of the transdifferentiation pro-
cess in HSC lacking endoglin. Inhibition is represented by a decreased amount of ECM
components, by alterations in the organization of the cytoskeleton and by a reduced
proliferation. Furthermore, a cDNA microarray was performed in order to designate
other mediators, which were differentially expressed in HSC lacking endoglin and con-
sequently influencing the phenotype. This array revealed many presumed candidates
amongst them genes such as α2-macroglobulin and ALK1. Based on their known func-
tions, these candidates might contribute to the phenotype of the endoglin deficient
HSC. Finally, stimulation experiments were performed in order to analyze the impact of
endoglin on the TGF-β and the BMP pathways. TGF-β1 and BMP-7, which are ligands
for endoglin, are important cytokines in the formation and the development of liver
fibrosis. Stimulation experiments were performed using TGF-β1 and BMP-7. Reporter
gene assay and Western blot analysis were used as read out systems.
Therefore, this research was crucial to demonstrate the importance of endoglin within
the process of HSC transdifferentiation. The knock down of endoglin in HSC interferes
with the transdifferentiation process and forces phenotypic alteration. Based on these
findings it can be assumed that endoglin has an important function within the process
of liver fibrogenesis.
ix
Chapter 1
Introduction
The transmission of information is one of the most important processes for every alter-
ing organic system.
By the advances of supply chain, transportation and the related information services
the world has become a complex network of information traffic. By using this network
the mankind is able to act and to influence processes far away from their own localiza-
tion. Especially nowadays a smooth transmission of information and goods is essential
for success.
Signal transduction, which is the transmission of information within a cell, between
two cells or within a complex cellular network is unique in its wide range of options.
Nevertheless, both structures have some basic principles in common. Starting with the
origin of information, followed by transmission and arrival, both result in influencing
their destinations. However, the transduction of information within a cell or an orga-
nism is the basic of a complex life. Therefore, problems occurring in this process, such
as missing or modified components, may result in serious consequences.
Exploring this complex field is essential in order to understand how cells commu-
nicate and how single components contribute to the final result. Eventually it will also
lead to an advancement in the basic knowledge for drug design.
1
1.1. Signal transduction
1.1 Signal transduction
1.1.1 General principles of signal transduction
Signal transduction describes the transfer of information within an organic system and
enables cells to communicate. The transfer can be either processed in an endocrine,
paracrine, autocrine, synaptical or cell-cell contact dependent manner. Except direct
cell-cell interaction through receptors, all the other interactions are mediated through
soluble signal molecules such as hormones, growth factors, interleukines, interferones
and chemokines.
Signal transduction starts with the specific binding of a ligand to its receptor. Sub-
sequently, the receptor becomes activated, thus, being able to activate down stream
components through conformational changes. Conformational changes are normally
induced by protein-protein interaction and especially by phosphorylation processes.
The activation of down stream components is accompanied by the amplification of the
signal. At the same time the receptor activation triggers a feedback circuit that shuts
off the receptor or removes it from the cell surface. This is called desensitization and
adaptation. Finally, the signal induces a cell response which results in e.g. enzyme pro-
duction, calcium release, cell migration, proliferation or apoptosis or induces further
cell-cell signaling. However, the final cell response is not the result of a single signal, it
is rather the integration of many signals. In this way the diversity of cell responses are
almost unlimited.
1.1.2 The TGF-β pathway
TGF-β is a multifunctional cytokine and, depending on the cell type, involved in the
regulation of many cell features such as proliferation, differentiation and migration.
In endothelial cells TGF-β plays a pivotal role in the development of the vessel wall.
Furthermore, TGF-β is the key cytokine regulating inflammatory processes as well as
fibrotic responses in the liver.
Prior to signaling the TGF-β precursor is cleaved by furin in the golgi membrane
[1]. Cleavage results in the small latent complex (SLC), which binds LTBP and forms
the large latent complex of TGF-β (LLC) [2]. Next, the large latent complex is secreted
and finally activated by proteolytic cleavage, resulting in the mature dimeric TGF-β
polypeptide [3] [4]. This TGF-β polypeptide is then able to bind to the TGF-β type II
receptor dimer. To this complex a type I receptor dimer is recruited forming a hetero-
tetrameric receptor complex [5]. After formation of the hetero-tetrameric receptor com-
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Figure 1.1: General principles of signal transduction. The transduction of a signal enables
cells to communicate and to perform adequate and specific cell responses. Cell signaling starts
with an external signal, which is received by a receptor, further transmitted inside the cell by
e.g. phosphorylation and ends in a cellular response such as enzyme production, calcium re-
lease or cell migration. Signal transduction is characterized by 1. ligand-receptor specificity,
2. the amplification of the signal, 3. desensitization/adaptation as a feedback loop to shut off
the receptor and 4. the integration of different signal.
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plex, the TGF-β type II serine/threonine kinase receptor is able to phosphorylate the
TGF-β type I serine/threonine kinase receptor [6]. Two distinct TGF-β type I receptors
can be activated by TGF-β, i.e. ALK5 and ALK1. The participation of ALK1 in TGF-β
responses has been first inferred from the vascular disease HHT2, which is caused by
haplo-insufficiency of ALK1 [7]. Later on the connection of ALK1 and TGF-β has been
established in cells derived from the corresponding mouse models [8]. Even though
ALK1 and ALK5 trigger opposite cell responses, it is supposed that both receptors are
able to cross talk [9]. In most cells TGF-β signaling is mediated via ALK5 activation. Ac-
tivated ALK5 mediates phosphorylation of Smad2 and Smad3 [11]. Smad2 and Smad3
as well as Smad1, Smad5, Smad7 and Smad8 belong to the receptor regulated Smads
(R-Smads). After phosphorylation the R-Smads dissociate from the activated receptor
complex, associate with common mediator Smad4 (Co-Smad) and translocate into the
nucleus [17]. Nuclear Smad oligomers bind to the DNA and regulate gene expression
[12], thus influencing cell proliferation, migration and with respect to the fibrotic re-
sponse the ECM expression [10] [13] [14]. Signaling via ALK5 is called the ”classical”
TGF-β pathway. In contrast to ALK5 activation the activation of ALK1 results in phos-
phorylation of Smad1 and Smad5. This in turn re-gulates cellular responses, which are
partially overlapping with ALK5 responses, e.g. proliferation and migration, but are
modified in an opposite manner. However, which receptor is activated depends on
the ligand concentration and the receptor expression [9] [10] [15]. Signaling via ALK1
is called the ”accessory” TGF-β pathway. Last but not least more components such as
SARA participate in the TGF-β pathway. SARA is an anchoring protein and recruits the
R-Smads [16]. Furthermore, ubiquitin dependent degradation and inhibitory Smad7 (I-
Smad) are involved in terminating and fine tuning of the signal [18] [19].
Beside TGF-β the corresponding superfamily encompasses bone morphogenetic
proteins, such as BMP-2, BMP-7 and BMP-9. Out of these cytokines BMP-7 is known
as an antagonist of the TGF-β1 signaling [20]. Similar to TGF-β, BMP-7 binds to BMP-
specific type I and type II membrane receptors, which leads to the activation of Smad1,
Smad5 and Smad8 [21]. Therefore, stimulation with TGF-β as well as stimulation with
BMP may result in the activation of partially overlapping target genes, but show at least
different kinetics [20] [22] [24].
Pathways, which were mentioned above, are not exclusively governed by the es-
sential receptors type I and type II. They are additionally modulated by the accessory
type III receptors betaglycan and endoglin (CD105) [15] [20] [23] [26]. Both receptors
have - as far as known - a more indirect role in TGF-β signal transduction, since they are
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not essential for signal transduction [25] [26]. Betaglycan facilitates the binding of all
three TGF-β isoforms to the TGF-β type II receptor, but especially facilitates the binding
of TGF-β2, which has a low affinity to the TGF-β type II receptor [26]. Endoglin modu-
lates signaling and binds TGF-β1, TGF-β3 and BMP-7 exclusively in the presence of the
type II receptors. [27] [46]. However, the role of betaglycan and endoglin might be un-
derestimated, because both receptors are necessary to maintain proper embryogenesis
[28] [29].
1.2 Endoglin
Endoglin is mainly linked to the autosomal dominant disorder hereditary hemorrhagic
telangiectasia type 1 (HHT1), also called Rendu-Osler-Weber disease [30]. This disorder
is caused by mutations in the endoglin gene and leads to haplo-insufficiency. Patients
with HHT1 show telangiectases on skin and mucosa as well as arteriovenous malfor-
mations in different organs including brain, lung, and liver [31] [32]. In contrast to
haplo-insufficiency the homozygous knock out of endoglin is lethal as demonstrated in
various mouse models. These mice show an arrest in the development of the vascular
system and die at E11.5 [28]. Due to the strong impact of endoglin on the phenotype
and its essential role in development, it is important to challenge the structure and cel-
lular functions of endoglin.
1.2.1 Structure of endoglin
Endoglin is a glycosylated type III TGF-β membrane receptor with a single transmem-
brane domain of 25 amino acids [33]. The extracellular domain encompasses the ligand
binding domain and the proteolytic cleavage side. Endoglin is expressed as a disulfide
homodimer and can be monomerized by reducing agents [34] [35] [36]. The very short
cytoplasmic domain is serine/threonine-rich and substrate for the TGF-β type I (ALK1,
ALK5) and type II (TβRII) kinases [37] [38]. In contrast to other receptors and especially
in contrast to the type I and type II TGF-β receptors, endoglin does not possess any ki-
nase activity in its short cytoplasmic domain (CD) [39]. Two serines, which are located
at the very end of the C-terminus of endoglin, are supposed to be constitutively phos-
phorylated by the TGF-βRII and three threonines are supposed to be phosphorylated
by ALK1 [37].
The initial mouse mRNA transcript of endoglin is detected as a 3.4-kb single trans-
cript by Northern blotting. To date two splice variants are known, L-endoglin as well
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Figure 1.2: The TGF-β and BMP-7 pathways. The ”classical” TGF-β pathway is activated
through binding of TGF-β to the TβRII. Endoglin as well as betaglycan are able to modulate
these binding processes. TβRII phosphorylates ALK5, which in turn phopshorylates either
Smad2 or Smad3. This is known as the ”classical” TGF-β pathway. The TβRII is also able to
phosphorylate ALK1, which in turn phopshorylates either Smad1, Smad5 or Smad8. This is
called the ”accessory” TGF-β pathway. Phosphorylated Smad1, Smad2, Smad3, Smad5 and
Smad8 associate with Co-Smad4, translocate into the nucleus and initiate the expression of spe-
cific target genes.
Phosphorylation of Smad1, Smad5 and Smad8 can also be induced by BMP-7. Upon binding of
BMP-7 to the BMP type II receptor, ALK2 becomes phosphorylated. Phosphorylated and thus
activated ALK2 is able to phosphorylate Smad1, Smad5 and Smad8. These R-Smads are finally
translocated into the nucleus.
Whereas betaglycan has been shown to promote the ALK5 pathway, endoglin most likely pro-
motes the ALK1 pathway and inhibits the ALK5 pathway, at least in endothelial cells. In addi-
tion it was recently shown that endoglin enhances BMP-7 signaling. However, the exact contri-
bution of endoglin is still under discussion.
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as S-endoglin. L-endoglin is the predominantly expressed form of endoglin and con-
sists of approx. 650 amino acids (mouse: 653 aa/ human: 661 aa) [34] [35]. S-endoglin
comprises approx. 617 amino acids and in comparison to L-endoglin, S-endoglin lacks
34 amino acids at the very end of the C-terminus. The short intracellular domain of
L-endoglin consists of 47 amino acids while the intracellular domain of S-endoglin con-
sists of 14 amino acids. Additional to the splice variants of endoglin, a soluble form of
endoglin is also known. Soluble endoglin is the result of shedding and represents the
shortest form of endoglin. The putative shedding side is located at amino acid 434-436
in rat endoglin. How this shedding is processed and which components are involved
is presently unknown. The molecular weight of endoglin is 95 kDa for the monomeric
form and 180 kDa for the dimeric form [34] [40].
Apart from endoglin a second TGF-β type III receptor exists, the so called betagly-
can. Betaglycan shows a broader expression pattern compared to endoglin and is ex-
pressed on hepatic stellate cells, too. Endoglin and betaglycan share a high homology
regarding their structure and regarding their amino acid sequence, especially at their
C-termini [36]. Furthermore, they have a single transmembrane domain with a very
short intracellular domain and they lack a catalytic domain. However, both receptors
comprise many serine and threonine residues and they are both capable of binding to
members of the TGF-β superfamily such as TGF-β1 and TGF-β3. One of the main func-
tions of betaglycan is to enhance the affinity of TGF-β2 to bind to the TGF-β type II
receptor [26].
1.2.2 Function of endoglin
Endoglin (L-endoglin) is highly expressed on endothelial cells [41], on mesenchymal
cells [42] [43] and on stromal cells [44]. Endoglin, as a TGF-β type III receptor, is able
to bind at least 6 different cytokines, which are all members of the TGF-β superfamily,
i.e. TGF-β1, TGF-β2, BMP-2, BMP-7, BMP-9 and activin [45] [46]. However, endoglin
can bind these cytokines only in association with the corresponding type II receptors
[46]. According to the ligand spectrum, endoglin modulates a diverse set of cellular
responses such as proliferation [23] [47], extracellular matrix (ECM) gene expression
[23] [48] and migration [49] [50]. Beside the potential to bind a diverse set of cytokines,
direct protein-protein interactions between endoglin and other proteins are described.
These interactions may govern the organization of the cytoskeleton in a ligand inde-
pendent manner [51] [52].
Even though endoglin seems to be involved in many cellular processes, the pre-
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Figure 1.3: The structure of endoglin. S-endoglin and L-endoglin have a single transmem-
brane domain and are expressed as a disulfide bound homo-dimer at the surface of cells. So
far, three variants of endoglin are known at least in human. L-endoglin, as the predominantly
expressed form of endoglin, S-endoglin and, finally, soluble endoglin, as the result of a shed-
ding process. Endoglin does not possess any kinase activity in its short cytoplasmic domain.
Instead of this, the cytoplasmic domain is serine and threonine-rich and can be phosphorylated
by the TGFβ type I (ALK1, ALK5) and type II (TβRII) receptors. Phosphorylation, which is
caused by the type II receptor, could be detected by an antibody recognizing a phosphorylation
of the NFκB subunit p65. On the other hand the antibody sc-6199, which is directed against
the C-terminus of endoglin, only binds when endoglin is not phosphorylated. The extracellular
domain possesses the ligand binding domain. Human endoglin additionally contains a RGD
domain, which is a key recognition structure in cellular adhesion [34].
8
1.2. Endoglin
cise functionality of endoglin is still poorly understood. The impact of endoglin on
the ”classical” pathways is putatively mediated by direct interaction of endoglin with
the signaling receptors [46] [53] [54] [55]. These interactions are regulated by phos-
phorylation of the cytoplasmic domain of endoglin [37] [38] [39]. In former studies
interactions of endoglin and signaling receptors were investigated. These studies re-
vealed that direct interaction of endoglin and ALK5/Smad2 affects eNOS expression
[38] [56], while interaction of endoglin and ALK5/Smad3 affects ECM expression [20]
[48] [57] and modulates proliferation and migration [20] [48] [57]. Furthermore, it has
been suggested that endoglin is involved in MAP kinase signaling, implicating JNK
and ERK1/2 MAP kinases [48] [58]. For example, the interaction of β-arrestin2 with the
cytoplasmic domain of endoglin leads to an activation of ERK1/2, thus, regulating en-
dothelial cell migration [59]. In addition, endoglin interacts with LIM-domain proteins.
Interaction with LIM-domain proteins such as Zyxin and Zyxin-related protein (ZRP)-1
[51] [52] is necessary for cytoskeletal organization and cellular migration. As described
above, endoglin is involved in several cellular processes and is essential for normal
cellular behaviour. As a consequence, a dysregulation of endoglin interferes with the
normal cellular function. Accordingly, endoglin is related to several pathogenic pro-
cesses including tumorigenesis and fibrosis [102] [61]. Furthermore, soluble endoglin is
a potential tumor marker not only for gastric cancer and prostatic adenocarcinoma [62]
[63].
To date the function of soluble endoglin and S-endoglin are less investigated. S-
endoglin was cloned from human and mouse [33] [64]. Due to the fact that L-endoglin
and S-endoglin differ in the C-terminus, which includes regulatory phosphorylation
sites and protein-protein interaction motifs, it was assumed that both splice variants
differ in their function [65]. Later on this assumption was experimentally proven [15]
[64] [65]. So far soluble endoglin is exclusively found in mammals and is especially
elevated in the sera of pre-eclamptic patients [66].
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1.3 The Liver
The easiest way to justify the importance and inalienability of every organ is their ex-
istence. However, the function of the liver and its involvement in many processes is
outstanding.
1.3.1 Function and anatomy of the liver
On the one hand the liver is the central organ of the intermediate metabolism such as
glyconeogenesis and glycogenolysis as well as degradation, conversion and assembly
of different lipids and the amino acids and protein metabolism. On the other hand the
liver stores a multitude of vitamins, especially vitamin B12 and metals such as iron and
copper and excretes bile, which is an important detergent to emulsify fats. Last but
not least the liver is involved in the decomposition of red blood cells and detoxification
[67].
In order to perform and hold up this wide range of duties, different cell types are
located in the liver and are necessary for proper functionality. Almost 60 - 70% of the
liver mass consists of hepatocytes [68]. Hepatocytes are parenchymal cells and most of
the metabolic activities in the liver take place in these cells. The other, second cell type,
which belongs to the parenchyma is the cholangiocyte. Cholangiocytes modify the
composition of the bile. Endothelial cells, Kupffer cells and hepatic stellate cells (HSC)
represent the non-parenchymal cell types. The sinusoidal endothelial cells are sepa-
rated from the hepatocytes by the space of Disse and are responsible for the uptake and
elimination of macromolecules from the blood. Kupffer cells, which are liver resident
macrophages, are attached to the sinusoidal wall and are in contact with the blood flow.
As macrophages they are involved in the immune response. HSC, also known as Ito-
cells, are fat and retinol (vitamin A) storing cells. They are located within the space of
Disse and they are attached to hepatocytes as well as in close interaction with hepato-
cytes. Furthermore, these cells are mainly responsible for the synthesis of extracellular
matrix (ECM) components such as collagen type I, III, and IV [69] [70]. Due to the im-
portant function of HSC during liver fibrosis, this cell type will be discussed in more
detail in the next subsection.
1.3.2 Function of HSC during liver fibrogenesis
HSC as a non-parenchymal cell type of the liver and TGFβ as an autocrine and paracrine
regulator of HSC physiology are intrinsically tied to the initiation process and the de-
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Figure 1.4: Architecture of a normal liver vs. liver with advanced fibrosis. The sinu-
soidal endothelial cells are separated from the hepatocytes by the space of Disse. In the normal
liver HSC are localized within the space of Disse and Kupffer cells are attached to the sinu-
soidal wall on the luminal side of the sinusoid. Upon noxae of different etiologies, Kupffer cells
become activated and produce fibrogenic mediators. Furthermore, hepatocytes become apop-
totic and release TGFβ and other fibrogenic mediators. Activated HSC transdifferentiate into
myofibroblast-like cells, migrate and accumulate at the site of tissue repair and synthesize ECM
components such as collagen type I and III. Additionally, inflammatory lymphocytes infiltrate
the hepatic parenchyma. With the loss of the fenestration character of the sinusoidal endothelial
cells the resistance to the blood flow increases and liver function decreases.
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velopment of liver fibrosis.
Liver fibrosis is the preliminary stage before liver cirrhosis and is associated with
the loss of liver function [72] [73]. In contrast to the traditional view, recent studies
indicate that even advanced fibrosis is reversible [74]. The loss of liver function is char-
acterized by hypertension, which is caused by a higher resistance to blood flow, and a
reduced exchange capacity of the sinusoid and the parenchyma, which is caused by the
loss of fenestration. This in turn is due to a massive formation of collagen and other
ECM components, which leads to an increase of connective tissue in the affected or-
gan [73]. HSC are the main source of ECM components such as collagen type I, III, IV
and fibronectin. Therefore, HSC are the key regulator of ECM synthesis during liver
fibrogenesis.
However, synthesis of ECM components is moderate in quiescent HSC. Prior to
ECM production, quiescent HSC need to be activated. Activation of HSC can either
be induced by cytokines, which originate from hepatocytes, Kupffer cells or sinusoidal
endothelial cells (paracrine stimulation) or by infiltrating lymphocytes, thrombocytes
and leukocytes. One of the most important cytokine for the initial activation process is
TGFβ. TGFβ is normally stored in hepatocytes and released in response to cell damage
[75]. After activation, HSC transdifferentiate into contractile, pro-inflammatory and
fibrogenic myofibroblast-like cells (MFB) [76] [77] [78] and migrate towards the trau-
mata. There they participate in the wound healing process by secreting ECM compo-
nents, thus forming the scar tissue. The formation of scar tissue is further supported by
a decreased ECM degradation [88] [89]. ECM degradation is caused by matrix metallo-
proteinases and their inhibition is due to an increased expression of the tissue inhibitors
of matrix metalloproteinases (TIMPs) [79] [80].
HSC once activated produce and secrete TGFβ resulting in an autocrine stimulation
of HSC and apoptotic hepatocytes. These reciprocal effects are the basis for a deregu-
lated wound healing process [81] [82]. However, a single noxis is insufficient to induce
a deregulated wound healing process. Instead of this many recurring persistent stimuli
have to occur, which lead to a deregulated wound healing process and finally to liver
fibrosis and cirrhosis [83] [84] [87].
In vitro the activation of HSC and transdifferentiation into MFB can be experimen-
tally induced. Activation and transdifferentiation in vitro is associated with the modifi-
cation of distinctive cell features/attributes. These modifications are comparable to the
modifications that occur in the in vivo situation (Figure 1.5) .
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Figure 1.5: Modification of distinctive cell features/attributes during in vitro transdif-
ferentiation of HSC. The arrows describe the changes of cell attributes as they occur in HSC
during transdifferentiation in vitro. X-axis: day of culture; Y-axis: attributes, which are modified
during transdifferentiation. While the number of lipid droplets and the amount of GFAP (glial
fibrillary acidic protein) is decreased during transdifferentiation the potential to proliferate and
migrate is increased. Furthermore, activation of HSC is accompanied by the induction of ECM
(extracellular matrix) components, α2-macroglobulin and α-SMA (alpha smooth muscle actin)
synthesis. Therefore, the expression of ECM components, the expression of marker proteins as
well as cellular function characterize the transdifferentiation process and they are helpful tools
to determine the stage of transdifferentiation.
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1.4 RNAi
In 2006 Andrew Z. Fire and Craig C. Mello were honored with the Nobel Prize in
Physiology and Medicine for their discovery of ”RNA interference - gene silencing
by double-stranded RNA”. Due to the immense and immediate impact of RNAi on
biomedical research Andrew Z. Fire and Craig C. Mello got the Nobel Prize - in contrast
to most of the other Nobel laureates - shortly after their first publication. Additionally,
the potential transfer of this method to novel medical applications in future emphasizes
the importance of this method.
1.4.1 RNAi as an experimental tool for sequence specific gene silencing
In 1998 Fire and co-workers were performing gene silence experiments with Caenorhab-
ditis elegans and antisense oligonucleotides (ASOs), when they found out that dsRNA
is more efficient for gene silencing than the corresponding antisense oligonucleotides
[90]. Although observations in former studies were obviously caused by RNA interfer-
ence, this observation by Fire and co-workers was finally the birth of RNAi. Due to the
fact that dsRNA interferes with the function of the target gene this new technology was
named RNA interference.
Even though the knowledge about RNAi is new, the mechanism itself is evolution-
ary conserved. This highly conserved character is due to the important biological func-
tion of siRNA such as the protection of cells against viruses and repetitive DNA ele-
ments [91]. Furthermore, RNAi is involved in a wide variety of cellular processes such
as the regulation of development, growth, differentiation, apoptosis and cancer [92]
[93]. However, for this thesis it might be sufficient to provide a short overview about
siRNA as an experimental tool for gene silencing in vitro. The starting point for RNA
interference is normally a double-stranded RNA (dsRNA) of approximately 100 nu-
cleotides. This dsRNA is recognized and digested by the Dicer into small interfering
siRNA of 21-23 nucleotides [94]. In case RNA interference is used as an experimental
tool, cells are directly transfected with either synthetic siRNA of 21-23 nucleotides or
with a vector, that allows stable expression of shRNA molecules (Figure 1.6). While syn-
thetic siRNA of 21-23 nucleotides are not processed by the Dicer, shRNA (short hairpin
RNA) is recognized and need to be digested by the Dicer. The Dicer is a RNAse type-
III enzyme, holding a dual catalytic domain and additional RNA helicase and PAZ
motif (putative protein-protein interaction domain) [95]. After digestion the siRNA en-
ters the RNA-induced silencing complex (RISC). For the incorporation of siRNA into
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Figure 1.6: RNAi as an experimental tool for sequence specific gene silencing. Cells are
directly transfected with either b) synthetic siRNA of 21-23 nucleotides or with a) a vector, that
allows stable expression of shRNA molecules. While synthetic siRNA of 21-23 nucleotides are
not processed by the Dicer, shRNA (short hairpin RNA) is recognized and digested by the Dicer
into siRNA of 21-23 nucleotides. siRNA of 21-23 nucleotides finally enter the RNA-induced si-
lencing complex (RISC) and become unwinded. Unwinding in turn activates the RISC complex
and guides the siRNA to the complementary target mRNA. After binding the target mRNA
is digested by the RISC complex. In this way RNA interference is able to silence genes in a
sequence-specific manner.
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the RISC complex the double-stranded feature and the two-nucleotides 3‘-overhangs
and 5‘-phosphate termini of the siRNA are functionally important [96] [97]. Incorpo-
ration is followed by unwinding of the siRNA [97] through the Piwi-Argonaute-Zwille
(PAZ) domain of Argonaute 2 [98]. This in turn activates the RISC complex and guides
the siRNA to the complementary target mRNA. Identification of the target mRNA is
due to Watson-Crick basepairing [99] and is followed by mRNA cleavage, which is per-
formed by the RNaseH-like structure of the argonaute 2 protein [98]. This cleavage is
endonucleolytic and occurs - at least in Drosophila - only in the region, which is ho-
mologous to the siRNA [100]. In this way RNA interference is able to silence genes in a
sequence-specific manner.
Nevertheless, there are several challenges that can occur by working with siRNA.
First of all partial sequence homology of the siRNA with other than the intended target
mRNA might lead to an inhibition of translation. This is comparable to the inhibition
of translation caused by miRNA [60] [101]. Furthermore, an interferon response might
lead to a shutdown of the global protein expression [103]. Such an interferon response
is normally restricted to oligonucleotides ≥ 30 [104], but might also occur by the use of
shorter siRNA, e.g. siRNA of 21 oligonucleotides [105]. These unintended effects are
called off-target effects.
Last but not least RNAi is also involved in the regulation of gene expression due to
its impact on heterochromatin assembly - at least in S. pombe - [106] [107]. Genes, which
are localized within the heterochromatin are transcriptionally silenced. Assembly and
spreading of heterochromatin in S. pombe is induced by histone H3 lysine 9 deacety-
lation, which is followed by methylation processes. Deacetylation and the following
methylation process can be initiated by the RITS complex (RNAi-induced transcrip-
tional silencing complex), which contains both a chromatin-associated protein and a
RNAi-associated protein [108]. The targeting of the RITS complex to heterochromatin
regions for inactivation requires siRNA binding [108]. In S. pombe most of the chromatin
modifications were restricted to known heterochromatic loci. However, recent investi-
gations in mammalian cells revealed that chromatin modifications can also occur at loci,
which are normally euchromatic [109]. In this case synthetic siRNA targeting CpG is-
lands induces DNA methylation, which in turn results in an repressed gene expression
at the transcriptional level [109].
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Aim of this study
The aim of this study was to investigate the function of endoglin in primary rat hepatic
stellate cells, especially with respect to the activation and transdifferentiation process.
For this purpose siRNA was used to down regulate endoglin. Subsequent endoglin de-
ficient cells were characterized and different aspects of the transdifferentiation process
such as ECM components, marker proteins and cellular features were analyzed.
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Chapter 2
Materials and methods
2.1 Plastic ware
Plastic ware Company
Cell culture 6 well plates Sarstedt, Germany
Cell culture 12 well plates BD Bioscience, USA
Cell culture 96 well plates BD Bioscience, USA
MicrotestTM 96-well Assay plate BD Bioscience, USA
Cell culture Dishes ∅ 60 mm Sarstedt, Germany
Cell culture Dishes ∅ 100 mm Sarstedt, Germany
Culture Slides 4 wells BD Bioscience, USA
CryoTubes Sarstedt, Germany
Falcon 50 ml Greiner, Germany
Gloves, powder free Sempermed, Austria
Immuno Module F16 Maxi Sorp NUNC, Germany
Immuno 96 Microwell Plates NUNC, Germany
Pipette tips 10 µl Eppendorf, Germany
Pipette tips 200 µl Eppendorf, Germany
Pipette tips 1000 µl Eppendorf, Germany
Safeseal pipette tips 10 µl Biozym, Germany
Safeseal pipette tips 200 µl Biozym, Germany
Safeseal pipette tips 1000 µl Biozym, Germany
Tissue Culture Flasks ∅ 550 ml Cellstar®, Germany
Tubes 1.5ml Sarstedt, Germany
Tubes 2 ml Sorenson Bio Science Inc., USA
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2.2. Equipment
Tubes low binding 0.5 ml Eppendorf, Germany
UltraClearTMTubes 7/16 x 2 3/8
11 x 60 mm
Beckman Coulter, USA
Table 2.1: Plastic ware
2.2 Equipment
Equipment Company
ABI 310 Genetic Analyzer Applied Biosystems, USA
Agarose gel electrophoresis system Febikom, Germany
Axiovert 135 M Microscope Zeiss, Germany
Beckman AvantiTMJ-15 Centrifuge Beckman Coulter, USA
Beckman Optima L-70k Ultracentrifuge Beckman Coulter, USA
Biometra WT16 (Rocking platforms) Biometra, Germany
Biometra T3 (Thermocycler) Biometra, Germany
Biofuge pico centrifuge Heraeus Instruments,
Germany
Biofuge 15R centrifuge Kendro Products, Germany
Cell Culture Incubator Heraeus, Germany
Gene Quant Pharmacia Biotech, USA
Ice machine Ziegra, Germany
INTAS DNA-Gel-documentation Imager INTAS, Germany
Leica DMLB Microscope Leica, Germany
Lumi-Imager ECL Boeringer, Germany
MicroBeta Jet 1450 Scintillation and Lumines-
cence Counter
PerkinElmer, USA
Microprocessor pH-Meter WTW, Germany
MilliQ Water Purification System Millipore S.A., France
Pipetman 10 µl Eppendorf, Germany
Pipetman 20 µl Eppendorf, Germany
Pipetman 100 µl Eppendorf, Germany
Pipetman 200 µl Eppendorf, Germany
Pipetman 1000 µl Eppendorf, Germany
Power PAC 300 BioRad, USA
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2.3. Chemicals
Sartorius 1364MP (analytical balance) Sartorius, Germany
Sartorius 1212MP (analytical balance) Sartorius, Germany
Thermomixer 5436 Eppendorf, Germany
Victor 1420 Multilabel Counter Wallac, Finland
Vortex Genie2 Fisher Scientific, USA
XCell SureLockTM Mini-Cell Invitrogen, USA
XCell II Blot Module Invitrogen, USA
Table 2.2: Equipment
2.3 Chemicals
Chemicals Company
Acetic acid Merck, Germany
Aceton Merck, Germany
Agarose seaKem® Cambrex, USA
BactoTM Agar BD Bioscience, USA
BactoTM Peptone BD Bioscience, USA
BactoTM Yeast Extract BD Bioscience, USA
Bicin AppliChem, Germany
Biotin Blocking Solution DakoCytomation, USA
Bis-Tris AppliChem, Germany
BrdU
BSA (Albumin, bovine serum) Sigma, Germany
Calcium chloride Merck, Germany
Caesium chloride MP Biomedicals, USA
Centrisep Spin Columns Princeton Separation, USA
ChemMate Peroxidase-Blocking Solution DakoCytomation, USA
Chlorobutanol Fluka, Austria
Chloroform Sigma, Germany
Chromatography paper 3MM Whatman, England
Collagen, Type 1 (rat tail) B&D, USA
Complete protease inhibitor cocktail Roche, Germany
DAPI Molecular Probes, USA
DMEM Cambrex, Belgium
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(Dulbecco’s Modified Eagle’s Medium)
DMSO (Dimethylsulfoxide) Fluka, Austria
DPBS Cambrex, Belgium
(Dulbecco’s Phosphate Buffered Saline)
DTT (1,4-dithiothreitol) Sigma, Germany
dNTP’s Roche, Germany
EDTA (ethylenediaminetetra acetic acid) Merck, Germany
Ethanol Roth, Germany
Ethidium bromide Sigma, Germany
Fast Red Tablets Roche, Germany
FCS (fetal calf serum) Perbio, Switzerland
Ficoll Amersham, Sweden
Fluorescent Mounting Medium DakoCytomation, USA
Formaldehyde (≥ 36,5 %) Roth, Germany
Formamide Fluka, Switzerland
FuGeneTM6 (Transfection Reagent) Roche, Germany
Gelatin Sigma, Germany
Glycerin Sigma, Germany
Guanidinthiocyanate Merck, Germany
HEPES Roth, Germany
Hybond-N membrane Amersham, Sweden
HiPerFect (Transfection Reagent) Qiagen, Germany
Isopropanol Roth, Germany
L-Glutamine Cambrex, Belgium
Lipofectamine®2000 (Transfection Invitrogen, USA
Reagent)
Lithium chloride Merck, Germany
Magnesium chloride Merck, Germany
MES Roth, Germany
(2-(N-morpholino)ethanesulfonic acid)
Methanol Roth, Germany
2-Mercaptoethanol Roth, Germany
MOPS Roth, Germany
(3-(N-morpholino)propanesulfonic acid)
Mounting Medium Faramount DakoCytomation, Denmark
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Nanofectin I (Transfection Reagent) PAA, Austria
Nycodenz Nyegaard, Norway
Nitrocellulose Membrane Schleicher & Schuell,
Germany
NuPage BisTris Gels 4-12 % Invitrogen, Germany
NuPage BisTris Gels 10 % Invitrogen, Germany
NuPage TrisAcetate Gels 3-8 % Invitrogen, Germany
NuPage LDS-sample-Buffer (4x) Invitrogen, Germany
NP-40 (Nonidet P40) Roche, Germany
Paraformaldehyde Merck, Germany
Penicillin/Streptomycine Cambrex, Belgium
Phenol Roth, Germany
Phosphatase Inhibitor Cocktail 2 Sigma, USA
PEG (Polyethylenglycol) Fluka, Switzerland
Potassium Phosphate (Dibase/Monobase) Merck, Germany
Poly-L-Lysine Solution Sigma, Germany
Potassium Chloride Merck, Germany
PVP (Polyvinylpyrrolidon) Sigma, Germany
RotiszintEcoplus Szintillator Roth, Germany
Sodium acetate Merck, Germany
Sodium azide Merck, Germany
Sodium carbonate Merck, Germany
Sodium chloride Roth, Germany
Sodium citrate Merck, Germany
Sodium hydrogen carbonate Merck, Germany
Sodium hydrogen phosphate monohydrate Merck, Germany
Sodium Hydroxide Merck, Germany
SDS (Sodium dodecyl Sulfate) Roth, Germany
Skimmed milk powder Roth, Germany
SuperSignal®West Dura Pierce Biotechnology, USA
Extended Duration Substrate
SYBR Green Roche, Germany
TCA (Trichloracetic Acid) Roth, Germany
Trizma®Hydrochloride Roth, Germany
Tricine Roth, Germany
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Triton X-100 Roth, Germany
Tween20 (polyoxyethylenesorbitan monolaure-
ate)
Roth , Germany
T4-Ligase Buffer Roche, Germany
X-ray film BioMax XAR Kodak, USA
Xylol Merck, Germany
Table 2.3: Chemicals
2.4 Radioactive materials
Material Company
[α32P]-dCTP Amersham Bioscience, England
3H-thymidine NEN Life Science Products, Germany
Table 2.4: Radioactive materials
2.5 Enzymes
Enzymes Company
Omniscript®Reverse Transcriptase Qiagen, Germany
BamHI NEB, USA
DNase type II Roche, Germany
EcoRI NEB, USA
HindIII NEB, USA
Gateway®LR ClonaseTMII Enzyme Mix Invitrogen, USA
Klenow-Fragment Roche, Germany
KpnI NEB, USA
MluI NEB, USA
NotI NEB, USA
PacI NEB, USA
ProteinaseK Sigma, Germany
Taq DNA Polymerase Roche, Germany
Trypsin (10x) PAA Laboratories, Austria
T4-DNA-Ligase Roche, Germany
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2.7. Cytokines
RNase Roche, Germany
SalI NEB, USA
XbaI NEB, USA
XhoI NEB, USA
Table 2.5: Enzymes
2.6 Molecular size standards
Standards Company
GeneRuler 100 bp DNA Ladder Plus Fermentas GmbH, Germany
HindIII ladder NEB, USA
SeeBlue Plus2 Pre-Stained Standard Invitrogen GmbH, Germany
Table 2.6: Molecular size standards
2.7 Cytokines
Cytokines Company
BMP-7 recombinant human R&D Systems, USA
TGF-β1 recombinant human R&D Systems, USA
Table 2.7: Cytokines
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2.8 Multicomponent systems
Multicomponent systems Company
Adeno-X- rapid Titer Kit BD Bioscience Clontech, USA
Annexin-V-FLUOS Staining Kit Roche, Germany
BigDye Terminator Cycle Sequencing Ready Reac-
tion Kit
Applied Biosystems, USA
BLOCK-IT Adenoviral RNAi Expression System Invitrogen, USA
DC Protein Assay BIO-RAD, Germany
Expand high fidelity PCR Systems Roche, Germany
EnzChek Gelatinase/Collagenase Assay Kit Invitrogen, USA
pGM®-T and pGEM®-T Easy Vector System Promega Corporation, USA
QIAquick Gel Extraction Kit Qiagen, Canada
RNeasy Mini Kit Qiagen, Germany
Steady Glo Luciferase Assay system Promega, Germany
SuperScript Reverse Transcriptase AMV Roche, Germany
Table 2.8: Multicomponent systems
2.9 Antibodies
Antibodies used in this study are listed in the table below. The antigen-antibody com-
plexes in Western blot analysis were detected by Supersignal®West Dura Extended Du-
ration Substrate.
2.9.1 First antibodies
Antibody Source Company
p-Smad3/1 (]9514) rabbit polyclonal Cell signaling, USA
human α2-macroglobulin (]15942) goat polyclonal Rockland, USA
rat α2-macroglobulin (R2M-25A-Z) rabbit polyclonal ICL, USA
rat Endoglin N-terminus (PPabE1) rabbit polyclonal Davids Biotechnologie,
Germany
rat Endoglin C-terminus (sc-6199) goat polyclonal SantaCruz, USA
β-Actin N-terminus (A5441) mouse monoclonal Sigma, Germany
human α-smooth muscle rabbit polyclonal Abcam, UK
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Actin N-terminus (ab5694)
rat Collagen IV full length (ab6586) rabbit polyclonal Abcam, UK
rat Collagen I full length (PS065) rabbit polyclonal Monosan, The Netherlands
rat Fibronectin full length (AB1954) rabbit polyclonal Chemicon Int.,
Germany
HSP70 C-terminus (sc-1060) goat polyclonal SantaCruz, USA
phospho-NF-κB rabbit polyclonal Cell signaling, USA
p65 Ser468 (]3039)
Table 2.9: First antibodies
2.9.2 Secondary antibodies
Antibody Source Company
rat IgG-HRP (sc-2006) goat polyclonal SantaCruz, USA
rabbit IgG-HRP (sc-2007) goat polyclonal SantaCruz, USA
mouse IgG-HRP (sc-2055) donkey polyclonal SantaCruz, USA
goat IgG-HRP (sc-2056) donkey polyclonal SantaCruz, USA
goat IgG-HRP (sc-2922) rabbit polyclonal SantaCruz, USA
Table 2.10: Secondary antibodies
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2.10 Microorganisms
2.10.1 Adenoviruses used in this study
Virus Source
Ad5-(BRE)2-luciferase this thesis
Ad5-(CAGA)12MLP-luciferase this thesis
Ad5-PU6-siEng this thesis
Ad5-PU6-siLacZ this thesis
Ad5-CMV-CRP2-GFP Prof. Weiskirchen
Ad5-CMV-CRP2 Prof. Weiskirchen
Table 2.11: Adenoviral strains used to infect hepatic stellate cells
2.10.2 E. coli strains used in this study
Strain Genotype Source
JM105 F’traD36 laclq∆ (LacZ)M15proA+B+/thi rpsL
(StrrendA sbcB15 sbcC? hsdR4 (r−K m
+
K )∆(lac-
proAB)
NEB, USA
One Shot®TOP10
Chemically Com-
petent
F-mcrA∆(mrr-hsdRMS- mcrBC)φ80lacZ∆M15∆
lacX74recA1araD139∆(ara-leu)7697galUgal
KrpsL (StrR) endA1nupG
Invitrogen, USA
Table 2.12: E. coli strains used in this study
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2.10.3 Eucaryotic cells used in this study
Strain Description Source
COS-7 African Green Monkey SV40-transformed ATCC, USA
kidney fibroblast cell line
293A established from primary embryonal kidney Invitrogen, USA
transformed with sheared humen Ad5 DNA
rHSC male Sprague-Dawley rat hepatic stellate cells this laboratory
mHSC male C57BL/6J mouse hepatic stellate cells this laboratory
Table 2.13: Eucaryotic cells used in this study
2.11 Oligonucleotides
Oligonucleotides used for sequencing
Gene Acc. No Fragment Primer
pAd- - - WV009 5’-(GAC TTT GAC CGT TTA CGT GGA GAC)-3’for
Block-iT WV010 5’-(CCT TAA GCC ACG CC ACA CAT TTC)-3’rev
pENTR4 - - WV013 5’-(GGA ACC AAT TCA GTC GAC TG)-3’for
WV014 5’-(GTA ACA TCA GAG ATT TTG AGA C)-3’for
Table 2.14: Oligonucleotides used for sequencing
Oligonucleotides used for PCR and Sequencing
Gene Acc. No Fragment Primer
eng AY562420 535 bp SM010 5’-d(CAG GCA TCC AAC ACC ATA G)-3’for
SM011 5’-d(CGA TGC TGT GGT TGG TAC)-3’rev
rzyxin XM216124 523 bp SM171 5’-d (CCT GCT TCA CTT GTC ATC)-3’for
SM172 5’-d (GGT GTG GAA GGA GGT CC)-3’rev
rzrp-1 AF120109 520 bp SM173 5’-d (GTC TGG AGT GGA GCA ACC)-3’for
SM174 5’-d (CGG TAG CAT AAG AGG CTG)-3’rev
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2.12. Oligonucleotides for gene silencing
rS6 NM017160 383 bp rS6s 5’-d(GAC TGA CAG ATA CCA CTG TGC CT)-3’for
rS6r 5’-d(TTA TTT TTG ACT GGA CTC AGA T)-3’rev
Table 2.15: Oligonucleotides used for PCR
Oligonucleotides used to generate the hybridization probes for Northern blotting
Gene Acc. No Fragment Primer
Eng AY562420 815 bp SM014 5’-d(CCA AGG CTG CCA CTT GG)-3’for
SM015 5’-d(TGC TCA CCT GTA CGA AGC)-3’rev
rα2M NM012488 570 bp WV022 5’-d(GTT GTC CGC AAT GCC CTC)- 3’for
WV023 5’-d(CAG GCA CAG TCG GCA ATG)-3’rev
rColIα 2 NM053356 787 bp WV026 5’-d( GCT CAG TAT TCT GAC AAA GG)- 3’for
WV027 5’-d(GAC CAG TGG CAC CAG CAG)-3’rev
rFn NM019143 604 bp WV028 5’-d(GCT GTG ACC CAG ACT TAC)-3’for
WV029 5’-d(CCG AAG CAG GTA CAG TTC)-3’rev
rAlk1 L36088 835 bp SM032 5’-d(CTA TCT CCA AGG ACC ATG ACC)-3’for
SM034 5’-d(GCT GCG TGC TGG AGT TCC G)-3’rev
rMMP10 NM133514 500 bp WV020 5’-d(CTC ATG CCT ACC CAC CTG)- 3’for
WV021 5’-d(CTG CCC AGA ACT GAC TTC C)- 3’rev
Table 2.16: Oligonucleotides used to generate the hybridiza-
tion probes
2.12 Oligonucleotides for gene silencing
siRNA oligonucleotides (Qiagen)
Gene Acc. No Order no. Oligonucleotide
Control NONE siRNA Alexa r(UUC UCC GAA CGU GUC ACG U)dtdt sense
Fluo Fluor 488 r(ACG UGA CAC GUU CGG AGA A)dtdt antisense
Control NONE AllStar siRNA Proprietary
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2.12. Oligonucleotides for gene silencing
α2M NM012488 Rn A2m 6 HP r(CCA UAA CCA AAC UAU CAU U)dtdt sense
r(AAU GAU AGU UUG GUU AUG G)dtdt antisense
α2M NM012488 Rn A2m 7 HP r(CCA ACU CGA ACA UCC GUA A)dtdt sense
r(UUA CGG AUG UUC GAG UUG G)dtdt antisense
Eng AY562420 Rn Eng 1 HP r(CCA UAU AUU UAC CAA UAA A)dtdt sense
r(UUU AUU GGU AAA UAU AUG G)dtdt antisense
Eng AY562420 Rn Eng 2 HP r(CAC UGC ACU UGG UCU ACA A)dtdt sense
r(UG UAG ACC AAG UGC AGU G)dtdt antisense
Table 2.17: siRNA oligonucleotides used for gene silencing
Oligonucleotides used to generate the shRNA viruses
Gene Acc. No Order no. Oligonucleotide
Eng AY562420 siRNA 12 5’-d(CAC CGC ACC CTC AGT TGC AAC TTA
GCG AAC TAA GTT GCA ACT GAG GGT GC)-3’
5’-d(AAA AGC ACC CTC AGT TGC AAC TTA
GTT CGC TAA GTT GCA ACT GAG GGT GC)-3’
Eng AY562420 siRNA 34 5’-d(CAC CGA AAG TCA GGC CTG TGA
TGG TGC GAA CAC CAT CAC AGG CCT GAC)-3’
5’-d(AAA AGT CAG GCC TGT GAT GGT
GTT CGC ACC ATC ACA GGC CTG ACT TTC)-3’
Eng AY562420 siRNA 56 5’-d(CAC CGA ATA GAT GTA CCA CAG
TGC AGC GAA CTG CAC TCT GGT ACA TCT A)-3’
5’-d(AAA ATA GAT GTA CCA GAG TGC
AGT TCG CTG CAC TCT GGT ACA TCT ATT C)-3’
LacZ siLacZ 5’-d(CAC CGC TAC ACA AAT CAG CGA
TTT CGA AAA ATC GCT GAT TTG TGT AG)-3’
5’-d(AAA ACT ACA CAA ATC AGC GAT
TTT TCG AAA TCG CTG ATT TGT GTA GC)-3’
Table 2.18: Oligonucleotides used to generate the shRNA
viruses
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2.13 Plasmids
Vector Description Source
CAGA (CAGA)12MLP in pGL3-Basic Vector Dennler et al., [110]
BRE (BRE)2 in pGL3-Basic Vector Korchynskyi et al., [111]
pENTR4 pENTRTM4 2,7kb Invitrogen, USA
pAd-Block-it pAd/BLOCK-iTTM-DEST 34864bp Invitrogen, USA
Mouse Endoglin mouse endoglin in pCMV-Sport6 RZPD, Germany
Rat Endoglin rat endoglin in pcDNA 3.1(+) Meurer et al., [36]
Table 2.19: Plasmids used in this study
2.14 Solutions and buffers
ddH2O was used as a solvent throughout this thesis.
Buffer/Solution Concentration
Ampicillin
ampicillin 10% (w/v)
in PBS (pH 7.4)
Blocking Solution Western blot
skim milk 5%
in TBST
Blocking Solution Immunohistochemistry
fish gelatin 0.1% (w/v)
BSA 1% (w/v)
in PBS (pH 7.4)
Collagen stock solution
acetic acid 0.1% (w/v)
collagen, Type 1 rat tail (2 mg/ml) 2.5% (w/v)
in ddH2O
CsCl-Buffer
CsCl 5,7 M
NaOAc (pH 6.0) 25 mM
in ddH2O
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Denhardt’s solution
BSA 1% (w/v)
PVP 1% (w/v)
Ficoll 400 1% (w/v)
in ddH2O
dNTPs
dATP 10 mM
dTTP 10 mM
dGTP 10 mM
dCTP 10 mM
in ddH2O
GIT-Buffer
Guanidinthiocyanate 4 M
NaOAc 25 mM
NaCl 100 mM
Mercaptoethanol 0,835% (v/v)
EDTA (pH 8.0) 1 mM
in ddH2O
HBSS
NaCl 0.137 M
KCl 5.4 mM
Na2HPO4 0.25 mM
K2HPO4 (pH 7.5) 0.44 mM
CaCl2 1.3 mM
MgSO4 1 mM
NaHCO3 4.2 mM
in ddH2O
Hybridization solution I
Formamid 50 % (v/v)
SSC 20x (pH 7.4) 30% (v/v)
EDTA 5 mM
Denhardt’s solution 50x 10% (v/v)
SDS 0.5% (w/v)
in ddH2O (pH 7.4)
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MEN-Buffer 10x
MOPS 200 mM
NaOAc 50 mM
EDTA 10 mM
in ddH2O (pH 7,0)
Herring sperm DNA
Herring sperm DNA 10 mg/ml
solved for 8 h at 4°C in ddH2O
MOPS SDS-Running-Buffer
MOPS 50 mM
Tris-HCl (pH 7.7) 50 mM
SDS 3.47 mM
EDTA 1.025 mM
in ddH2O
PBS
NaCl 137 mM
KCl 2.7 mM
Na2HPO4 8 mM
K2HPO4 (pH 7.5) 50 mM
in ddH2O pH 7.3
Permeabilization buffer 10x
Triton X-100 0.1% (v/v)
KCl 2.7 mM
in PBS
4% PFA
Paraformaldehyde 4% (w/v)
adjusted with NaOH 2M
in PBS (pH 7.4)
Potassium phosphate buffer
K2HPO4 1 M
KH2PO4 1 M
in ddH2O
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RIPA lysis buffer
Tris 20 mM
NaCl 150 mM
NP-40 2% (v/v)
SDS 0.1% (w/v)
DOC 0.5% (w/v)
adjusted with HCl 2M
in ddH2O (pH 7.2)
RNA running buffer
Formaldehyde 4% (v/v)
in MEN-buffer 1x
RNA sample buffer
Formaldehyde 6% (v/v)
Formamide 70% (v/v)
Bromphenol Blue 0.03% (v/v)
Ficoll 400 1% (v/v)
store at -20°C in MEN-Buffer 1x
Solution I
Glucose 50 mM
EDTA 10 mM
Tris-HCl 25 mM
in ddH2O (pH 8.0)
Solution II
SDS 1%
NaOH 0.2 M
in ddH2O
Solution III
KOAc 3 M
acetic acid 5.75% (v/v)
in ddH2O
SSC (20x)
NaCl 3 M
tri-Sodiumcitrate 300 mM
in ddH2O
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DNA sample buffer (5x)
EDTA 20 mM
Glycerin 30% (v/v)
SDS 0.5% (v/v)
Bromphenol blue 0.1% (w/v)
in ddH2O
TBS (10x)
Tris-HCl (pH 8.0) 100 mM
NaCl 1.5 M
in ddH2O
TBS-T
Tris-HCl (pH 8.0) 100 mM
NaCl 1.5 M
Tween-20 0.1% (v/v)
in ddH2O
TBE-Buffer
Tris Base 89 mM
Boric acid 89 mM
EDTA 1 mM
in ddH2O
Transfer-Buffer (Western blot)
Bicine 25 mM
Bis-Tris 25 mM
EDTA 1 mM
Chlorobutanol 0.05 mM
Methanol 10% (v/v)
in ddH2O
Tris-Acetate Running-Buffer (Western blot)
Tris-HCl (pH 7.7) 50 mM
Tricin 50mM
SDS 0.1% (w/v)
in ddH2O
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Wash solution I (Northern blot)
SSC (20x) 10% (v/v)
EDTA 1 mM
SDS 0.1% (w/v)
in ddH2O
Wash solution II (Northern blot)
SSC (20x) 2% (v/v)
EDTA 1 mM
SDS 0.1% (w/v)
in ddH2O
Table 2.20: Buffers and solutions
2.15 Media for cell culture
Media for E. coli
LB 0.5% yeast extract
1% tryptone
0.5% NaCl
final pH 7.5; use NaOH
LB-Amp LB
add Ampicillin to a final conc. 50 µg/ml
LB-Kan LB
add Kanamycin to a final conc. 50 µg/ml
SOC 1x SOB-media
after autoclaving 20 mM glucose
Table 2.21: Media for E. coli
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Media for hepatic stellate cells
DMEM 10% FCS DMEM media
(Culturing) 10% fetal calf serum
100 mg/ml Streptomycin
100 U/ml Penicillin
4 mM L-Glutamine
DMEM 0.5% FCS DMEM media
(Starvation) 0.5% fetal calf serum
100 mg/ml Streptomycin
100 U/ml Penicillin
4 mM L-Glutamine
DMEM 0.2% FCS DMEM media
(Stimulation) 0.2% fetal calf serum
100 mg/ml Streptomycin
100 U/ml Penicillin
4 mM L-Glutamine
Table 2.22: Media for hepatic stellate cells
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2.16 Analytical methods
2.16.1 Calculation of DNA concentration
The concentration and purity of DNA was determined by measuring the absorbance at
260 nm using a spectrophotometer.
c(dsDNA) in
µg
ml
= OD260 · dilution f actor · 50 (2.1)
c(ssDNA) in
µg
ml
= OD260 · dilution f actor · 33 (2.2)
Pure DNA solution has a ratio of OD260nm and OD280nm between 1.8 and 2.0.
2.16.2 Calculation of RNA concentration
The concentration and purity of RNA was determined by measuring the absorbance at
260 nm using a spectrophotometer.
c(ssRNA) in
µg
ml
= OD260 · dilution f actor · 40 (2.3)
Pure RNA solution has a ratio of OD260nm and OD280nm between 1.9 and 2.1.
2.16.3 Calculation of adenoviral stock concentration
After cloning, amplification and purification of the adenoviral stock (chapter 2.20), 40 µl
of the viral stock was diluted 1:25 in ddH2O and the OD260nm was measured. As a
reference 40 µl of formulation buffer was also diluted with 960 µl of ddH2O. Based on
OD260nm the concentration of viral particles was calculated as followed:
Particles
ml
= OD260 · 1.1 · 1012 · 25 = x · 10
12Particles
ml
(2.4)
”Particle” include intact and infectious viruses as well as damaged, non-infectious
viruses. Therefore, the concentration of plaque forming units have to be further de-
termined. The conversion of particle to plaque forming units (Pfu) was based on the
experience value of the technician, meaning 4 particles correlate with approximately 1
Pfu.
38
2.17. Cell culture methods
2.16.4 Calculation of protein concentration
The protein concentration was determined using the DC protein assay. The concentra-
tion of standard samples have been between 0.6 µg/µl and 1.8 µg/µl. The DC protein
assay was performed according to the manufacturer’s instructions. The absorbance
was measured in a 96-well plate at 690 nm using the Victor 1420 Multilabel Counter.
2.17 Cell culture methods
2.17.1 Culture conditions of E. coli
E. coli cells were cultured either in LB medium at 37°C and 180 rpm or on LB agar plates
at 37°C. Depending on the plasmid and it’s resistance gene antibiotics were added to
the LB medium and to the LB agar plates with a final concentration of 50 µg/ml for
ampicillin and kanamycin. Positive transformants were selected on these plates.
2.17.2 Culture conditions of COS-7
COS-7 cells were cultured at 37°C in a CO2 incubator with a concentration of 5% CO2
and 100% relative humidity.
Culturing of COS-7 cells was performed in DMEM, enriched with 10% (v/v) FCS,
L-glutamine (4 mmol/liter), penicillin (100 IU/ml) and streptomycin (100 µg/ml)
2.17.3 Coverglass preparation for microscopy
For microscopy of cultured hepatic stellate cells, cells were seeded onto cover glass. Prior
to the experiment cover glasses were incubated in 25% hydrochloric acid for 8 h at
37°C, washed with MilliQ and stored in 70% EtOH at 4°C. One day before seeding
cover glasses were shortly heated up in order to vaporize EtOH, placed in one well of a
6-well-plate and covered with DMEM containing 10% FCS. The next day medium was
removed and cells were seeded and cultured as described below.
2.17.4 Isolation of rat hepatic stellate cells
Isolation of HSC was performed by a technician. Briefly, HSC were isolated from male
Sprague-Dawley rats by the Pronase-collagenase method followed by a density cen-
trifugation on a Nycodenz gradient. Livers were perfused with Hanks’ buffered saline
solution (HBSS) and subsequently with 0.35% (w/v) Pronase E and 0.015% (w/v) colla-
genase, both in HBSS. Afterwards, the liver was dissected in HBSS supplemented with
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DNase type II (100 µg/ml) and filtered through a nylon mesh. The resulting cell suspen-
sion was centrifuged, and cells were washed in ice-cold HBSS containing 0.25% (w/v)
bovine serum albumin. HSC were further purified on 8.25% (w/v) Nycodenz gradi-
ents. The mean purity was estimated by vitamin A autofluorescence. The yield ranged
from 20 to 50 x 106 HSC/liver. According to the growth area the number of cells was
adjusted as listed below. Cells were initially cultured in HEPES-buffered Dulbecco’s
modified Eagle’s medium supplemented with L-glutamine (4 mmol/liter), penicillin
(100 IU/ml), streptomycin (100 µg/ml), and 20% FCS [113].
growth area number of cells
64 cm2 2.5-3 ·106
28 cm2 0.8-1 ·106
10 cm2 0.3-0.5 ·106
12 well 0.09-0.15 ·106
24 well 0.05-0.08 ·106
2.17.5 Culture conditions of rat hepatic stellate cells
Hepatic stellate cells were cultured at 37°C in a CO2 incubator with a concentration of 5%
CO2 and 100 % relative humidity.
Culturing of HSC was performed in DMEM, enriched with 10% FCS, L-glutamine
(4 mmol/liter), penicillin (100 IU/ml) and streptomycin (100 µg/ml) as described in
2.22. Medium was renewed every second day with prewarmed medium. Prior to stim-
ulation experiments, cells were starved in DMEM enriched with 0.5% FCS for 16 h.
Stimulation itself took place in DMEM enriched with 0.2% FCS. Throughout starvation
and stimulation medium was enriched with L-glutamine, penicillin and streptomycin.
The only exception was transfection using Lipofectamine as described in 2.19.10. In this
case DMEM without additives was used.
2.17.6 Stimulation of rat hepatic stellate cells
Stimulation of hepatic stellate cells was performed in DMEM enriched with 0.2% FCS, L-
glutamine, penicillin and streptomycin. Before stimulation cells were starved in DMEM
enriched with 0.5% FCS, L-glutamine and penicillin for 16 h. Cells were stimulated for
8-12 h with either TGF-β1 or BMP-7 with a concentration of 1 ng/ml or of 50 ng/ml,
respectively. Afterwards, cells were harvested and according to the experimental pro-
cedure further processed.
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2.18 Biochemical methods
2.18.1 Preparation of total protein lysate from rat hepatic stellate cells
Hepatic stellate cells were washed twice in ice-cold PBS. According to the size of the
culture dish, cells were lysed in 200 µl - 600 µl RIPA buffer. RIPA buffer contained
the complete protease inhibitor cocktail and depending on the experiment RIPA buffer
was enriched with a Phosphatase inhibitor cocktail (1:100). Lysis was supported by
additional shearing through a 0.4 x 19 mm needle and the lysate was further incubated
on ice for 30 minutes. Afterwards, the lysate was centrifuged at 4°C and 13 000 rpm in
a table top centrifuge. The pellet was discarded and the supernatant was used for SDS
polyacrylamide gel electrophoresis and Western blot analysis.
2.18.2 SDS polyacrylamide gel electrophoresis
SDS polyacrylamide gel electrophoresis was used to separate denatured proteins ac-
cording to their molecular weight. To determine the weight of the proteins molecular
weight markers (2.3) were used. Protein concentration was determined as described
in 2.16.4. Equal amounts of protein were diluted with 4 x LDS electrophoresis sam-
ple buffer (2.3). Depending on the experiment DTT was added as a reducing agent
(final concentration 10 mM). After incubation for 10 min at 70°C proteins were sepa-
rated on either 4-12% Bis-Tris gradient gels (2.3) using MOPS-SDS running buffer or
alternatively on 3-8% Tris-Acetate gradient gels (2.3) using Tris-Acetate SDS running
buffer. Depending on the experiment 10 µg or 20 µg of protein was loaded on the gel
and separated at 140 V for about 2.5 h.
2.18.3 Western blot
Immunoblotting was performed using a wet transfer system. Proteins were transferred
onto a nitrocellulose membrane at 55 V for 3 h. To reduce non-specific binding of an-
tibodies the nitrocellulose membrane was initially blocked for 20 min with 5 % skim
milk powder in TBS-T, followed by over night incubation with the primary antibody.
Primary antibodies were detected with horseradish-peroxidase (HRP)-conjugated sec-
ondary antibodies. The secondary antibody was incubated for 5-6 h. Before and after
incubation with the secondary antibody the nitrocellulose membrane was washed three
times with TBS-T. Finally, the secondary antibody was detected with the SuperSignal
West Dura Extended Duration Substrate. All antibodies were diluted in 5% (w/v) skim
milk powder in TBS-T.
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2.18.4 Luciferase assay
HSC were either transfected with (BRE)2-Luc and (CAGA)12MLP-Luc in pGL3 as de-
scribed in 2.19.10 or infected with the corresponding (BRE)2-Luc and (CAGA)12MLP-
Luc adenovirus as described in 2.19.11. After transfection or infection, the cells were
cultured for at least 24 h. Prior to stimulation with TGF-β1 or BMP-7 cells were starved
in DMEM containing 0.5% of FCS instead of 10% FCS. After stimulation for 6 h or
12 h cells were washed twice with PBS. Cell lysis buffer, which was supplied with the
Steady-Glo-Luciferase Assay system was diluted 1:5 with ddH2O. 350 µl of cell lysis
buffer was added to the HSC and incubated for 1 minute. Cells were scraped off using
a rubber policeman and further homogenized using a 0.4 x 19 mm needle. The samples
were centrifuged in a table top centrifuge at maximal speed at 4°C for 15 minutes. The
supernatant was transferred to a new reaction tube.
LAR substrate was diluted 1:2 with ddH2O. 100 µl LAR was filled in one well of a
black 96 well plate. 20 µl of the cell lysate was added and mixed by pipetting. Fluo-
rescence was determined using the MicroBeta Jet 1450 Scintillation and Luminescence
Counter.
2.18.5 Proliferation assay
HSC were seeded onto 12-well plates and cultured in DMEM containing 10% FCS. One
day after initial plating, cells were transfected with siRNA as described in 2.19.10. On
day 2 of culture the medium was renewed. One day later the medium was replaced
again with 1 ml of DMEM containing 10% FCS and cells were exposed to 75 kBq/ml
[methyl3H]-thymidine for a 24 h labelling period. In case of BrdU, medium was re-
newed on day 4 and afterwards cells were exposed to BrdU for a 48 h labelling period.
Radioactivity incorporated into DNA was measured using the Microbeta 1450 Jet Scin-
tillation and Luminescence counter. BrdU incorporation was measured by a colorimet-
ric BrdU cell proliferation ELISA according to the manufacturer’s instructions (Roche).
2.18.6 Gelatinase assay
HSC were cultured in 96-well plates and DMEM containing 10% FCS. One day after
initial plating, cells were transfected with siRNA on day 1 as described in 2.19.10. On
day 4 the gelatinase/collagenase assay was initiated and fluorescence was measured at
530 nm at the indicated time points according to the manufacturer’s instructions.
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2.19 Molecular biological methods
2.19.1 Isolation of plasmid DNA (Miniprep)
E. coli were grown over-night in 2-3 ml LB medium containing the corresponding an-
tibiotics. The next day cells were pelleted by centrifugation for 1 minute at 13 000 rpm
in a table top centrifuge. The supernatant was discarded. The cell pellet was resolved
by vortexing in 100 µl solution I and incubated at room temperature for 5 minutes. To
lyse cells 200 µl of solution II was added and the reaction tube was inverted for a couple
of times until the solution became clear. After incubation for additional 5 minutes on
ice 150 µl of solution III was added and again incubated for 5 minutes on ice. Precip-
itation of protein started. After incubation 100 µl of chloroform was added, vortexed
and centrifuged for 10 minutes at room temperature and 13 000 rpm in a table top cen-
trifuge. After centrifugation the sample contained two phases. The upper, aqueous
layer contained the DNA. This aqueous layer was transferred to a new reaction tube,
1 ml of ice cold abs. ethanol was added and incubated for 5 minutes on ice. Samples
were centrifuged for 10 minutes at 13 000 rpm and 4°C in a table top centrifuge. The
supernatant was discarded, 1 ml of 70% ethanol was added to the pellet and again
centrifuged for 10 minutes at 13 000 rpm and 4°C in a table top centrifuge. The super-
natant was discarded, the pellet was air dried for 15-30 minutes and finally resolved in
50-100 µl ddH2O. The DNA concentration was determined as described in 2.16.1.
2.19.2 Isolation of RNA
For isolation and purification of total RNA from hepatic stellate cells the RNeasy Mini
Kit from Qiagen was used. Briefly, cells were washed twice with ice cold PBS and de-
pending on the number of cells 300 µl or 500 µl of RLT buffer containing 1% (v/v)
β-Mercaptoethanol were added. Cells were scraped off using RNase free tissue cell
rubber policeman. Cells were then homogenized using a 0.4 x 19 mm needle and the
QIAshredder spin columns. The samples were further processed as described in the
instruction manual. Finally RNA was eluted in 30 µl RNase free ddH2O. The concen-
tration of the total RNA was determined as described in 2.16.2. RNA was stored at
-80°C.
2.19.3 Formaldehyde agarose gel electrophoresis
Isolation of total RNA was performed as described before (2.19.2). Because Ribonucle-
ases (RNases) are very stable and active enzymes possible RNase contaminations were
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eliminated as followed. Glassware was washed and oven baked at 180°C over-night.
Electrophoresis tanks, gel slides and other hard plastic components were treated with
2% SDS solution for 3-4 h. MilliQ water that was used to set up buffers was autoclaved
in RNase free glassware. Furthermore, sterile, disposable polypropylene plastic ware
was used. Throughout the experiment gloves were worn.
To separate total RNA a formaldehyde agarose gel containing 2% (w/v) agarose and
17% (v/v) formaldehyde in 1 x MEN-buffer was prepared as followed. 146 ml water
and 2 g agarose were heated in a microwave until agarose was completely dissolved.
Prior to adding 20 ml of 20 x MEN-buffer and 34 ml of formaldehyde the solution was
cooled down to 65°C and finally poured onto a gel support. 5 µg or 10 µg of total RNA
were diluted with 1.5 volumes of RNA sample buffer and incubated for 10 min at 70°C.
1 µl of ethidium bromide was added to the sample. The sample was loaded onto the
gel. The gel was run at 30 V until the bromphenol blue band had passed three-quarter
of the gel. Prior further processing images were taken under UV light.
2.19.4 Northern blot
To transfer RNA from agarose gel to a nitrocellulose membrane a plastic dish, slightly
larger than the agarose gel was used as electrophoresis tank. The tank was filled with
20 x SSC transfer buffer. A plastic plate was arranged on the edges of the plastic dish.
Whatmann paper, which was soaked with 20 x SSC, were placed on the plastic plate
touching the transfer buffer and mediating the buffer flow. Air bubbles were removed
by rolling a 10 ml sterile plastic pipet over the surface of the whatman papers. Af-
terwards the gel was placed upside down on the whatman papers and topped with a
nitrocellulose membrane. It was important to avoid bubbles at this step. In order to
maintain that the buffer pass through the gel, the gel was surrounded with strips of
plastic wrap.
Three more whatman papers were placed on the nitrocellulose. Air bubbles were
removed using a sterile plastic pipet. Finally, a big layer of paper towels and a glass
plate were placed on top. To ensure good contact between the gel and nitrocellulose
and to hold everything in place a weight was placed on the glass plate. The transfer
was performed over-night.
The next day paper towels and whatman papers were removed. The position of
wells, the direction of sample loading as well as 18S and 28S RNA were marked. The
membrane was placed in between two whatman papers and air dried for at least 30 min-
utes. The RNA was immobilized by baking at 80°C for 2 h. The membrane was either
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immediately used or stored at -80°C.
Labelling of DNA probes
DNA probes used for RNA detection were either obtained by restriction digestion or by
PCR using the corresponding pGEMT-easy vector. DNA was purified by agarose gel
extraction as described before (2.19.8). Approximately 100 ng of double-stranded DNA
were diluted with water to a final volume of 10 µl. Samples were heated for 3 minutes
in boiling water and transferred on ice. Primer (5 µl), buffer solution (10 µl), MilliQ
(18 µl), 5 µl [α32P] dCTP (∼ 3000 Ci/mmol) and Klenow fragment (2 U) were added
and incubated for 2 h at 37 °C. Non incorporated nucleotides were separated from the
DNA probe by a G50-Sephadex column. The column consists of a Pasteur pipette and
a glass ball slightly sealing the Pasteur pipette. The Pasteur pipette was filled with
G50-Sephadex. TES was used as running buffer and for equilibrating the column. The
labelling sample was loaded onto the G50-Sephadex column and eluted with TES. The
fractions (1st fraction: 600 µl next fractions 200 µl each) were collected. 1 µl of each
fraction was counted in a liquid scintillation counter. Fraction 2 + 3, which contained
the radioactive labelled probe, were pooled, denatured for 10 minutes at 95°C and used
for the hybridization.
Hybridization
The nitrocellulose membrane was placed in a hybridization tube. 1 ml Hybridiza-
tion solution I per cm2 supplemented with herring sperm DNA (final concentration:
100 µg/ml) were added and incubated for 3 h at 37°C and 60 Upm. The Hybridization
solution I was replaced by 1 ml Hybridization solution I per 5 cm2. Radioactive labelled
DNA probe was added to the hybridization tube to a final concentration of 1 million
counts/ml and incubated for 16 h at 37°C and 60 Upm. Afterwards the membrane was
washed once with wash solution I for 20 minutes at 55°C, followed by washing twice
with wash solution II for 20 minutes at 50°C. Finally autoradiography was performed.
2.19.5 cDNA synthesis
cDNA synthesis was performed according to the instruction manual using the Super-
script II Reverse Transcriptase Kit (Invitrogen). Briefly, 1 µg of total RNA, 1 µl random
primer (250 ng/µl) and 1 µl dNTPs (10 mM) were diluted with H2O to a final volume
of 13 µl. To avoid regions of double-stranded RNA sample was heated for 5 minutes
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at 65°C. After heating the reaction tube was immediately transferred on ice and 4 µl of
5 x buffer and 2 µl of DTT 0.1 M were added and carefully mixed. Prior to adding 1 µl
of super script II reverse transcriptase the sample was incubated for 2 minutes at 25°C.
After adding reverse transcriptase the sample was incubated for 10 minutes at 25°C,
followed by 1 h at 42°C and 15 minutes by 70°C. For long term storage cDNA samples
were kept at -20°C.
2.19.6 Polymerase chain reaction (PCR)
Polymerase chain reaction was used to amplify DNA sequences for cloning or sequenc-
ing. 100-200 ng of Plasmid or cDNA, 1 µl of forward and reverse primer (0.1 µg/µl),
2.5 µl of 10 x buffer, 0.5 µl dNTPs (10 nM), 1 µl of Taq DNA Polymerase were diluted
with ddH2O to a final volume of 25 µl.
Depending on the lengths of DNA fragments and the relation between purines and
pyrimidines a program similar to the program shown below was set up in a Robocycler.
1 Denaturing 5 min 95°C
2 Denaturing 30 s 95°C
3 Annealing 30 s 54°C
4 Elongation 90 s 72°C
Step 2-4 25-35 cycles
5 Holding temperature unlimited 4°C
To perform a semi-quantitative PCR the number of cycles and the amount of cDNA
were reduced as much as possible.
2.19.7 DNA sequencing
For sequence validation of PCR and cloning products DNA sequencing was performed.
During the sequencing reaction fluorescent dye labelled dideoxynucleotides were intro-
duced into the sequence. This caused an arrest of the extension and resulted in frag-
ments of different sizes, containing an end labelled dideoxynucleotide. For each reac-
tion 8 µl Terminator Ready Reaction Mix, 400 ng DNA and 40 ng sequencing primer
were diluted with H2O to a final volume of 20 µl. Because the Terminator Ready Reac-
tion Mix does contain the polymerase each step was performed on ice. The sequencing
reaction program was set up as follows:
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1 Denaturing 5 min 95°C
2 Denaturing 30 s 95°C
3 Annealing 20 s 50°C
4 Elongation 4 min 60°C
Step 2-4 50 cycles
5 Holding temperature unlimited 4°C
The sequencing products were purified using Centrisep Spin Columns. Prior to
purification 800 µl of H2O was loaded onto the column and incubated for at least 3 h.
Afterwards, the top and bottom lid was removed, the column was placed in a reaction
tube and centrifuged for 2 min at 750 g. The column was transferred to a new reaction
tube, the sequencing reaction was loaded onto the column and again centrifuged for
2 min at 750 g. The flow through contained the purified sequencing products and was
further processed by drying in a vacuum centrifuge for 20 minutes. The sample was
resolved by a technician and analyzed using ABI 310 Genetic Analyzer or stored at
-20°C before sequencing.
2.19.8 Cloning
Agarose gel electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments of different sizes. De-
pending on the DNA fragment size the percentage of agarose varied between 0.7% and
2.0%. Agarose was dissolved in TBE-buffer and heated up in a microwave until agarose
was completely dissolved. 2-4 µl EtBr were added. The gel solution was mixed, poured
onto a gel support and run at 75 V for 2-3 h. DNA/EtBr complexes were visualized by
UV light and images were taken.
Isolation of DNA fragments by gel extraction
DNA fragments were separated by agarose gel electrophoresis. DNA fragments of in-
terest were excised with a scalpel and purified using the QIAquick Gel Extraction Kit
(Qiagen). The gel extraction was performed as recommended by the manufacturer.
Finally DNA was eluted with 30 µl - 50 µl ddH2O.
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Digestion of DNA
For cloning strategies plasmids and DNA fragments were specifically cut using restric-
tion enzymes. According to the restriction enzyme the buffer-system as recommended
and supplied by the manufacturer was used. The total volume of the reaction was 20 µl,
containing 0.5 - 2 µg DNA, 2 µl 10x buffer, 1 U of Enzyme and if recommended 0.1%
BSA. Incubation time was 1-3 h at 37°C. After digestion DNA fragments were separated
on an agarose gel. DNA of interest was gel extracted as described in 2.19.8.
Klenow reaction
The Klenow enzyme was used for complete filling of 3‘ recessed DNA ends. 3’ recessed
DNA are the product of some restriction enzymes, which produce sticky ends. The
standard reaction mix contained 1 µg DNA, 1 µl of NTPs (10 mM), 4 µl 10 x filling
buffer (M-restiction buffer) and 2 µl Klenow enzyme (2 U/µl). ddH2O was added to a
final volume of 40 µl. The sample was incubated for 60 minutes at 37°C followed by
inactivation at 65°C for 10 minutes.
Dephosphorylation of plasmid-DNA
In order to avoid self-ligation of single cut DNA fragments phosphate groups were
removed from the 5’-end of the DNA using calf intestinal alkaline phosphatase (CIP) as
recommended by the manufacturer. Briefly, dephosphorylation reaction contained 1 µg
DNA, 4 µl 10 x dephosphorylation buffer, 2 U of alkaline phosphatase and was diluted
with water to a final volume of 40 µl. The reaction was incubated for 60 minutes at 37°C
followed by inactivation of the enzyme at 65°C for 10 minutes.
Ligation of DNA fragments
Ligation reactions were performed in a total volume of 20 µl. The ligation reaction
contained 2 µl of 10 x T4-DNA-Ligase-buffer, 1 µl of T4 DNA-Ligase and the digested
and eventually dephosphorylated vector DNA as well as the DNA fragment of interest
in a molar ratio of 1:3. The reaction was incubated over-night at 16°C or for 1-2 h at room
temperature. E.coli were directly transformed with the ligation reaction as described in
2.19.9.
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2.19.9 Transformation
Heat shock transformation of E. coli
E. coli (DH5α cells) were transformed with DNA using the heat shock method. Cells
were thawed on ice, 0.5-2 µg of DNA was added, mixed and kept on ice for 30 minutes.
E. coli were heat-shocked at 42°C for 60 - 90 sec, immediately placed on ice and kept
in LB-medium for 30-60 min at 37°C. For selection E. coli were spread on LB plates
containing the appropriate antibiotics and grown over-night at 37°C. Single colonies
were then grown in LB media containing the appropriate antibiotics. Plasmids were
isolated as described in 2.19.1.
2.19.10 Transfection
Transfection of 293A cell line
Plasmid transfection into 293A cells was exclusively part of adenovirus production and
is described in detail in 2.20.3.
Transfection of COS-7
COS-7 cells were seeded onto 6 well plates (150 000 cells/well). The next day medium
was renewed one hour before the transfection was performed.
For each well 1 µg of DNA was placed in a reaction tube. In a second reaction tube
3 µl FuGene (for each µg of DNA) was diluted with 100 µl DMEM, gently vortexed,
centrifuged and incubated for 15 minutes at room temperature. After incubation the
FuGene solution was added to the DNA and incubated for 15 minutes. Finally the
solution was drop-wise added to the medium and incubated for 24 h before medium
was exchanged.
Transfection of hepatic stellate cells
HSC were isolated and seeded on 6-well plates. The next day medium was replaced
with DMEM supplemented with L-glutamine (4 mmol/liter), penicillin (100 IU/ml),
streptomycin (100 µg/ml) and 10% FCS (v/v). Medium was renewed every second
day and additional 2-3 h prior to transfection. For each well 1 µg of DNA was diluted
with 100 µl 150 mM NaCl, gently vortexed and briefly centrifuged. In a second reaction
tube 6 µl Nanofectin (for each µg of DNA) was also diluted with 100 µl 150 mM NaCl,
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gently vortexed and briefly centrifuged. Afterwards the Nanofectin solution was trans-
ferred to the DNA solution, mixed by tapping and incubated for 30 minutes at room
temperature. Finally the solution was added drop-wise to the medium and incubated
for 24 h before medium was changed.
Transfection of hepatic stellate cells with siRNA
HSC were isolated and seeded onto 12-well plates, 6-well plates or 60 mm dishes.
The next day medium was replaced with DMEM supplemented with L-glutamine (4
mmol/liter), penicillin (100 IU/ml), streptomycin (100 µg/ml) and 10% FCS (v/v) and
incubated for 4 h. After incubation cells were transfected according to the manufac-
turer’s instruction with a final siRNA concentration of 5 nM unless otherwise indicated.
The ratio of siRNA (20 µM) and HiPerFect was 1:20 (v/v). Depending on the experi-
mental procedure, medium was renewed every 48 h. Specific siRNAs targeting rat
endoglin (SI01509963, SI01509970) or rat α2-macroglobulin (SI03028361,SI03108518) or
siRNA control (1027281) were used. After establishing this method every experiment
was performed using SI01509970 in case of endoglin and SI03028361 and SI03108518 in
case of α2-macroglobulin.
2.19.11 Infection
Depending on the experimental setup hepatic stellate cells were infected with adenovirus
between day 1 and day 3 of culturing. Unless otherwise indicated, the cells were in-
fected with 1 · 108 Pfu/ml in DMEM containing 10% FCS. The medium was renewed
12 h after infection. Depending on the experiment cells were starved for 16 h and stimu-
lated as described in 2.17.6 or further cultured and processed for Western blot analysis.
2.20 Adenoviruses
As part of this thesis adenoviruses for reporter gene assays and adenoviruses for gene
silencing were constructed, produced, amplified and purified.
2.20.1 Generation of the shRNA expression vector
For creating the shRNA expression vector the instruction manual was followed accu-
rately. Briefly, two complementary oligonucleotides encoding shRNA of interest were
annealed to create a double-stranded oligo and directly ligated into the pENTRTM/U6
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vector. The pENTRTM/U6 vector represents the shuttle vector. E. coli was transformed
with this shuttle vector and selected for recombinant clones. The functionality of the
shuttle vector was tested in COS-7 cells.
The recombinant viral vector was generated by performing LR recombination re-
action using the shuttle vector pENTRTM/U6 containing shRNA and the pAd/Block-
itTMDest vector. Top10 E. coli were transformed with the LR reaction mixture and se-
lected for expression clones.
2.20.2 Generation of the (BRE)2 and (CAGA)12MLP luciferase shuttle vec-
tors
For generating the (BRE)2 luciferase and (CAGA)12MLP luciferase shuttle vector the
pGL3-Basic vector containing either (CAGA)12MLP Luc or (BRE)2 Luc (see Appendix
for plasmid maps) were double digested with BamHI and KpnI. pENTR4 was digested
with EcoRI and both digestion reactions were seperated on a 1% agarose gel. DNA
fragments were isolated as described in 2.19.8. The 3‘ recessed DNA ends of both DNA
fragments were filled using the Klenow enzyme as described in 2.19.8. The pENTR4
fragment was additionally dephosphorylated and the ligation was performed over-
night with the corresponding insert as described in 2.19.8. E. coli were transformed
with the ligation reaction and selected for recombinant clones.
The recombinant viral vector was generated by performing LR recombination reac-
tion using the shuttle vector pENTR4 containing either (CAGA)12MLP Luc or (BRE)2
Luc and the pAd/Block-itTMDest vector. The LR reaction mixture were transformed
into Top10 E. coli and selected for recombinant clones.
2.20.3 Production and amplification of adenoviral stocks
293A cells were used to produce the adenovirus. The adenoviral expression vectors
were cut with Pac I. 293A cells were transfected with the digested epression vector us-
ing Lipofectamine 2000 as transfection reagent. Prior to transfection cells were seeded
in a 6-well plate and cultured in normal growth medium containing 10% FCS. Cells
were grown until a confluence of 80% was reached. Transfection of the expression
vector in different concentrations but with a fixed ratio of 1:3 (Vector (µg) : Lipofec-
tamine 2000 (µl)) was performed according to the manufacturer’s instructions. The
next day medium was replaced and one day later cells were trypsinized and seeded
onto a 10 cm culture plate. Every second day medium was replaced and cells were
thoroughly monitored until regions of cytopathic effects were visible. Cytopathic ef-
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fects were indicated by patches of rounding, dying cells. When cytopathic effects were
visible, the medium was either partly replaced or fresh medium was added. When
approximately 90% of the cells showed the cytopathic effect, cells were harvested and
a crude viral lysate was prepared by three freeze/thaw cycles in liquid nitrogen fol-
lowed by centrifugation for 20 minutes at 4°C and 3 000 g. The supernatant contained
the crude viral lysate.
The crude viral lysate was diluted and used to infect 16 flasks of 293A cells. After
2-3 days most of the cells had a round shape and were floating within the medium. The
medium, which contains the floating cells was transferred to a falcon tube. Attached
cells were harvested, added to the falcon tube and centrifuged for 20 minutes at 4°C and
900 g. The supernatant was discarded and the pellet was further purified as described
next.
2.20.4 Purification of adenoviral stocks
The pellet enriched with infected 293A cells was resuspended in DMEM to a total vol-
ume of 14.7-14.8 ml. Cells were lysed by three freeze/thaw cycles in liquid nitrogen fol-
lowed by centrifugation for 20 minutes at 4°C and 3 000 g. The supernatant contained
the viral lysate. The lysate (14.7-14.8 ml) was mixed with 8 g of CsCl and 4 x 4.1 ml were
transferred to a centrifuge tube. The CsCl gradients were ultra centrifuged for 22-24 h
at 4°C and 40 000 rpm using a SW60Ti rotor. Via ultra centrifugation three different
bands were visible in the gradient. The top band contained debris of cells and medium,
the middle faint band contained damaged virus and the lowest band contained intact
virus. The CsCl solution containing the debris and damaged virus was removed using
a syringe. The CsCl solution enriched with intact virus was afterwards removed using
a fresh syringe and further purified using the Adeno-X-rapid Titer Kit.
Two filter steps are applied when the Adeno-X-rapid Titer Kit is used. Since the
virus was already purified by using the CsCl gradient the bottle top filter was skipped.
Furthermore, Benzonase was not used. Except this modifications the purification was
performed according to the instruction manual. Briefly, the Adeno-X syringe-filter was
washed with 50 ml PBS, loaded onto the Adeno-X syringe-filter, washed with wash
buffer and eluted with 3 ml 1 x elution buffer. The eluate was centrifuged for 30 min
at 12 000 rpm and 4°C. The supernatant was discarded and the pellet was resolved in
a total volume of 1260 µl Formulation buffer. The adenoviral titer was determined as
described in 2.16.3.
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2.20.5 CRP2-adenovirus
Adenoviral vectors expressing the cysteine rich protein 2 (CRP2) or a green fluores-
cent protein (GFP)-tagged version of CRP2 were cloned using standard procedures and
were provided by Prof. R. Weiskirchen. Briefly, expression cassettes directed under
transcriptional control of the CMV promoter were cloned into shuttle vector p∆E1sp1A
(Microbix Biosystems Inc., Ontario, Canada) and subcloned into the adenoviral back-
bone vector pJM17 (Microbix Biosystems) by homologous recombination in 293A cells.
Recombination, amplification and purification of respective adenoviral particles was
performed as described above.
2.21 Whole rat genome oligo microarray
Gene expression analysis of different rat mRNAs using agilent whole genome oligo
microarrays was performed by Miltenyi Biotec GmbH. Isolation of total RNA and parts
of the final data analysis was performed independently from Miltenyi as a part of this
thesis.
2.21.1 Sample preparation and quality check
HSC were isolated and seeded on 6 mm cell culture dishes. On day 1 of culture cells
were transfected with siRNA as described in 2.19.10. On day 8 of culture total RNA was
isolated (2.19.2) and the concentration of RNA was determined as described in 2.16.2.
Silencing of endoglin on the level of mRNA was demonstrated by semi quantitative
PCR as described in 2.19.6. Out of these samples 18 vials (6 groups each consisting
of Control, siEndoglin and siControl samples) were shipped to Miltenyi on dry ice for
further quality checks using the agilent 2100 bioanalyzer platform. For more detail
information see: www.miltenyibiotec.com. Finally four groups were chosen to perform
the hybridization (see table 2.23).
2.21.2 Hybridization
Before hybridization three different groups -each group consists of Control, siEndoglin
and siControl samples- were pooled. One group was further processed without pool-
ing. The selection of oligo(dT)-positive mRNAs, sample labelling and microarray hy-
bridization was performed by Miltenyi Biotech according to the agilent 60-mer oligo mi-
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crorray processing protocol using the agilent gene expression hybridiztion kit. The hybridiza-
tion schedule was as followed:
Exp No. Cy5 / Cy3 Array No.
1 1 (Con) 3 (siCon) 251487910880 1
2 2 (siEng) 3 (siCon) 251487910880 2
3 Pool 1 (Con) Pool 3 (siCon) 251487910880 3
4 Pool 2 (siEng) Pool 3 (siCon) 251487910880 4
Table 2.23: Microarray hybridization schedule
2.21.3 Data analysis
The fluorescence signals of the agilent oligo microarray were detected using agilent’s
DNA microarray scanner and further processed with the agilent Feature Extraction
Software. The complete raw data set and a putative candidate gene list were obtained
from Miltenyi. The putative candidate gene list contained genes with a fold change≥ 2
and p-value≤ 0.01. Additional to these basic information Miltenyi performed pathway
gene analysis.
The putative candidate gene list was further processed as part of this thesis. Genes
which were differentially expressed in hybridization no.1 (single) and no.3 (pool) were
excluded from hybridization no.2 (single) and no.4 (pool). In this way genes, which
were differentially expressed by the transfection itself, were skipped. Genes were also
skipped, if they were differentially expressed in only one of the hybridization no.2 (sin-
gle) or no.4 (pool). The remaining genes of hybridization no.2 (single) and no.4 (pool)
were defined as differentially expressed as a result of endoglin silencing.
2.22 Microscopy
2.22.1 Bright field microscopy
For bright field microscopy, cells were seeded on plastic dishes and cultivated as de-
scribed in 2.17.5. Cells were washed with PBS and images were taken using a 10 x objec-
tive and a 10 x ocular lens. Documentation of representative eye fields was performed
with a HV-C20 digital camera (HITACHI Denshi Ltd., Tokyo, Japan) or a KY-F75U
digital camera (HITACHI) and the DISKUS software package version 4.14 (Hilgers,
Ko¨nigswinter, Germany).
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2.22.2 Immunofluorescence microscopy
For immunofluorescence microscopy, the cells were seeded onto cover slides and cul-
tivated for the appropriate time period. Cells were once washed with PBS, fixed for
20 min in 4% PFA, permeabilized for 5 min with 0.1% Triton X-100 in phosphate buffer
and twice washed with PBS. The Alexa Fluor 488 Phalloidin stock solution was diluted
1:50 with PBS. PBS was removed and cells were stained for 40 min using 200 µl of
the diluted Phalloidin solution. Cells were washed three times with PBS. Nuclei were
counterstained with DAPI (1 µg/ml) for 1 min and washed with PBS and water. Fi-
nally, cells were mounted in antifade mounting medium (DAKO) and the cover slide
was placed on a glass slide.
When GFP-tagged proteins such as CRP2-GFP were visualized no permealization
was performed. Cells were directly counterstained, washed and mounted. Images
were taken using 10 x objective, a 20 x objective or a 40 x objective and a 10 x ocular
lens. Documentation of representative eye fields was performed as described above.
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Results
In order to characterize HSC, which express less endoglin compared to wild type HSC,
heterozygous knock out mice were initially analyzed. (Homozygous knock out of
endoglin is lethal during early embryogenesis [28].) First experiments revealed only
marginal changes in the quantity of endoglin in heterozygous knock out mice com-
pared to wild type mice. In addition preparation of HSC from endoglin deficient an-
imals was difficult to accomplish, because of the vascular malformation. This malfor-
mation leads to a disruption of vessels during the perfusion procedure. Therefore, it
was not possible to keep on working with heterozygous knock out mice. Instead, it
was necessary to search for an alternative method to knock down endoglin in vivo and
in vitro, respectively. The most promising method was the use of RNA interference.
For in vivo experiments an adenovirus, carrying the genetical information for shRNA
targeting mouse endoglin, was generated. For in vitro experiments primary rat HSC
were transfected with siRNA oligonucleotides targeting rat endoglin. Due to the fact
that in vivo experiments are very time-consuming they have not been performed yet.
However, based on a very efficient and sustained knock down of endoglin in vitro it
was possible to investigate the function of endoglin in HSC.
This thesis can be roughly divided into two sections. Experiments of the first section
analyze the function of endoglin under normal growth conditions (10% FCS). These
experiments revealed changes in morphology, in ECM abundance, in organization of
the cytoskeleton, in proliferation and in the gene expression pattern of HSC lacking
endoglin. Experiments of the second section analyze the involvement of endoglin in
the TGF-β1 and BMP-7 pathway after cell starvation (0.5% FCS) and stimulation (0.2%
FCS). Due to the fact that primary HSC are very difficult to transfect, but easy to infect,
a (CAGA)12MLP-luciferase virus and a (BRE)2-luciferase virus were generated. Beside
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Western blot analysis these viruses were used as an additional read out system for TGF-
β1 and BMP-7 stimulation experiments.
shRNA Virus siRNA Oligonucleotides
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Figure 3.1: The cartoon gives a short overview of the main experiments, which were performed
in this thesis.
Please note: Unless otherwise indicated, all experiments were performed with pri-
mary rat hepatic stellate cells (HSC). All time data indicate the day after initial plating of
HSC.
3.1 RNAi - Inhibition of endoglin expression in HSC
RNA interference (RNAi) describes the inhibition of eukaryotic gene expression by
double-stranded RNA (dsRNA). Inhibition of gene expression is due to a degradation
of messenger RNA (mRNA) complementary to the dsRNA. In vivo dsRNA is processed
into 21-23 nucleotide double-stranded short interfering RNA (siRNA). siRNA leads to
specific degradation of complementary mRNA. Short hairpin RNA (shRNA) is an ar-
tificial designed dsRNA. This dsRNA is processed to siRNA which in turn leads to a
specific degradation of mRNA.
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3.1.1 shRNA virus
In order to perform in vivo experiments three shRNA viruses were generated. For this
purpose, different double-stranded oligonucleotides encoding shRNA targeting mouse
endoglin were ligated into the pENTRTM/U6 vector (shuttle vector). These three con-
structs were termed shRNA 12.1, shRNA 34.1 and shRNA 56.1. As a negative control
double-stranded oligonucleotides encoding shRNA targeting LacZ were used. Prior to
homologous recombination the ability of these shRNAs to silence mouse endoglin was
tested in COS-7. COS-7 do not express endogenous endoglin. Therefore, COS-7 were
(double) transfected with the shRNA shuttle vector construct and additionally with an
expression vector encoding mouse endoglin. After transfection, cells were cultured for
4 days. Western blot analysis was performed and revealed shRNA 12.1 as the construct,
which down regulates mouse endoglin most efficiently (Fig. 3.2 a). Double transfection
of either shRNA 12.1 and shRNA 34.1 or shRNA 12.1 and shRNA 56.1 did not increase
gene silencing compared to shRNA 12.1 applied alone.
Subsequent to COS-7 experiments, shRNA 12.1 and shRNA 34.1 were subcloned
by homologous recombination into the pAd/Block-itTM-Dest vector. After subcloning
adenoviruses were amplified and the crude viral lysates were tested. Mouse HSC were
infected on day 2, cultured and harvested on day 7. Western blot analysis was per-
formed. Endoglin and α-SMA were detected using specific antibodies. As expected,
mouse HSC infected with shRNA LacZ did not show any decrease in endoglin expres-
sion (Fig. 3.2 b). Single infection of mouse HSC with a virus encoding shRNA 34.1 as
well as double infection with a virus encoding shRNA 34.1 and shRNA 12.1 resulted
in a decrease in endoglin expression. Depending on the virus concentration down-
regulation of endoglin was more efficient at higher concentration. α-SMA expression as
a marker for transdifferentiation was not affected in any sample analyzed. Single infec-
tion with the adenovirus encoding shRNA 12.1 had no impact on endoglin expression.
This is contrary to the results obtained in COS-7 experiments. While in COS-7 endoglin
was sufficiently silenced using shRNA 12.1 (Fig. 3.2 a) in mouse HSC, endoglin is un-
affected using shRNA 12.1 (Fig. 3.2 b). Therefore, the adenovirus carrying shRNA 34.1
is appropriate for endoglin down-regulation and suited for in vivo experiments.
3.1.2 siRNA oligonucleotides
In order to perform in vitro experiments siRNA oligonuclotides targeting rat endoglin
were used. First of all the transfection efficiency of primary HSC with siRNA oligonu-
cleotides was determined using fluorescence-labelled siRNA oligonucleotides and HiPer-
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Figure 3.2: shRNA testing in COS-7 and HSC. (a) Western blot analysis of COS-7 trans-
fected with three different shRNAs in pENTRTM/U6 was performed. 20 µl protein lysate were
loaded onto a 4-12% Bis-Tris gel. COS-7 were single transfected with an expression vector en-
coding mouse endoglin were used as positive control (lane 1). Untransfected COS-7 were used
as negative control (lane 2). COS-7 were double transfected with an expression vector encoding
mouse endoglin and with the shuttle vector containing either shRNA 12.1, shRNA 34.1, shRNA
56.1 or shRNA LacZ (lane 3-6). COS-7 were triple transfected with an expression vector en-
coding mouse endoglin in combination with the shuttle vectors shRNA 12.1 and shRNA 34.1 or
shRNA 12.1 and 56.1 (lane 7-8). shRNA 12.1 down regulates endoglin most efficiently compared
to the other shRNA constructs. PonceauS staining was used as a loading control. (b) Western
blot analysis of mouse HSC infected with different shRNA constructs on day 2 and harvested
on day 7 was performed. 20 µl protein lysate were loaded onto a 4-12% Bis-Tris gel. After dilu-
tion of the crude viral lysates (1:10 or 1:5) mouse HSC were either single infected with shRNA
LacZ virus, with shRNA 12.1 virus, with shRNA 34.1 virus (lane 1-6) or double infected with
shRNA 12.1 virus and shRNA 34.1 virus (lane 7-8). As an internal control uninfected mouse
HSC were used (lane 9). To investigate the transdifferentiation process α-SMA expression was
analyzed. Protein standard size markers are indicated in the left margin. HSP70 was used as a
loading control.
shRNA 34.1 virus silenced endoglin most efficiently. There were no differences towards the
double infection. shRNA 12.1 virus did not down regulate endoglin in mouse HSC. Down-
regulation of endoglin in HSC was more efficient when HSC were infected with higher concen-
trations of virus.
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Fect as transfection reagent (Fig. 3.3 a). HSC were transfected with different concentra-
tions (5 nM, 10 nM, 15 nM) of fluorescence-labelled siRNA oligonucleotides. HiPerFect
was used as transfection reagent. The next day, medium was renewed and images of
HSC were taken under UV-light. Untransfected HSC (Con) were used as negative con-
trol. HSC successfully transfected with fluorescence-labelled siRNA showed little spots
of green fluorescence. Number and intensity of green spots increased with an increase
in siRNA concentration. This experiment revealed that transfection of primary HSC
with siRNA is realizable using HiPerFect as transfection reagent.
Next, three aspects regarding the silencing efficiency were tested, i.e. concentration
(Fig. 3.3 b), double vs. single transfection (Fig. 3.3 c) and detection of first silencing
effects (Fig. 3.3 d). Two different siRNAs targeting endoglin were obtained by Qiagen
and used for double transfection experiments. Unless otherwise mentioned, a mix-
ture of 2 siRNA oligonucleotides targeting endoglin was used. On day 1 HSC were
transfected with different concentrations of siRNA. The final concentration of siRNA
oligonucleotides in the culture medium was either 0.16 nM, 0.31 nM, 0.63 nM, 1.25 nM,
2.5 nM or 5 nM. The ratio of siRNA to HiPerFect was constant. HSC transfected with
scrambled siRNA (siCon) and untransfected HSC (Con) were used as negative controls.
Knock down efficiency increased constantly when the concentration of siRNA was
raised. In order to test the ability of each siRNA to down regulate endoglin, HSC were
single transfected on day 1 (Fig. 3.3 c). Untransfected HSC (Con) were used as a con-
trol. siRNA 2 targeting endoglin was able to down regulate endoglin more efficiently
than siRNA 1 targeting endoglin. Double transfection of both siRNA oligonucleotides
did not enhance the efficiency of siRNA 2. Finally, down-regulation of endoglin during
the first two days after transfection was analyzed (Fig. 3.3 d). HSC were transfected on
day 1 with two different concentrations of siRNA oligonucleotides targeting endoglin.
Subsequent to transfection of siRNA endoglin expression was unaffected, but 24 h af-
ter transfection endoglin expression was already significantly reduced. At that time
suppression of endoglin was more efficient when siRNA was applied in higher concen-
trations. In HSC harvested 48 h after transfection endoglin was almost abolished. At
that time endoglin suppression was reduced independent of the initial siRNA concen-
tration.
Parameters for optimizing HSC transfection with siRNA oligonucleotides were de-
termined by the experiments described above. Based on these results, the remaining
experiments were performed with a final concentration of 5 nM siRNA using siRNA
oligonucleotide 2 targeting endoglin (Rn Eng 2 HP Qiagen). For simplification siRNA
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Figure 3.3: Determination of the transfection efficiency of fluorescence-labelled siRNA
oligonucleotides as well as analysis of the knock down efficiency of siRNA oligonu-
cleotides targeting endoglin. (a) Transfection efficiency was tested using increasing concen-
trations (5 nM, 10 nM and 15 nM) of fluorescence-labelled siRNA. Therefore, HSC were trans-
fected with siRNA oligonucleotides on day 3. On day 4 pictures were taken under UV-light.
Untransfected HSC (Con) were used as control. (b, c, d) Western blot analysis was performed
to analyze down-regulation of endoglin. (b, d) On day 1 HSC were transfected with a mix-
ture (1:1) of two different siRNA oligonucleotides targeting endoglin. (b) The ability of siRNA
oligonucleotides to down regulate endoglin was tested using different concentrations (0.16 nM,
0.31 nM, 0.63 nM, 1.25 nM, 2.5 nM, 5 nM) of siRNA. Untransfected HSC (Con) and HSC trans-
fected with scrambled siRNA (siCon) were used as negative controls. PonceauS stain was used
as a loading control. (c) siRNA oligonucleotides 1 and 2 were transfected separately on day 1.
As negative control a protein sample of untreated HSC was analyzed. (d) The ability of each
siRNA to silence endoglin was analyzed at different time points after transfection. HSP70 was
used as loading control (c, d). Protein standard size markers are indicated in the left margin (b,
c, d).
Green spots of fluorescence-labelled siRNA became visible at a concentration of 10 nM. Sig-
nificant changes in endoglin expression were first observed at a final concentration of 0.63 nM
siRNA. Down-regulation of endoglin was maximal at a final concentration of 5 nM. siRNA 2 re-
vealed a stronger down-regulation of endoglin compared to siRNA 1. Immediately after trans-
fection of HSC on day 1, the expression of endoglin was unaffected. However, suppression of
endoglin reached a value of 50-70% after 24 h and a value of 95-98% after 48 h.
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oligonucleotide 2 targeting endoglin will be termed ”siEng” and scrambled siRNA will
be termed ”siCon” in the following paragraphs.
3.1.3 Knock down of endoglin in HSC
Silencing of endoglin using siRNA was further examined with respect to following
questions. How long remains endoglin down regulated? Is the inhibition of endoglin
expression due to a degradation of messenger RNA or due to disturbance of the trans-
lational process?
To determine how long endoglin remains silenced, HSC were transfected on day
1 and harvested on the days 2, 6, 11 and 17. Cell lysates were analyzed by Western
blotting using a specific antibody against endoglin (Fig. 3.4 a). Endoglin was found
to be silenced at least until day 17. No recovery of endoglin expression was detected
in any experiment. Therefore, this method is appropriate to mediate a very strong and
long lasting knock down of endoglin. To determine, if inhibition of endoglin expres-
sion is due to degradation of mRNA, HSC were transfected on day 1 and harvested
on day 4. mRNA was isolated and cDNA was synthesized. Comparative RT-PCR was
performed for endoglin and for specific transcripts of the ribosomal S6 protein (Fig.
3.4 b). Additional to comparative RT-PCR, Northern blot analysis was performed. For
Northern blot analysis 5 µg of total RNA, which was obtained from HSC harvested
on day 8, were loaded onto each lane and analyzed with probes specific for endoglin
and GAPDH (Fig. 3.4 c). GAPDH was used as a loading control. In accordance with
Western blot analysis comparative RT-PCR as well as Northern blot analysis showed a
very efficient reduction of endoglin mRNA in HSC transfected with siEng. Therefore,
endoglin down-regulation is due to degradation of mRNA.
To exclude apoptosis as the reason for the sustained knock down a TUNEL test
was performed (Fig. 3.4 d). Subsequent to isolation, HSC were seeded on glass slides
and transfected with siRNA on day 1. On day 8 HSC were fixed with 4% PFA and
incubated with the TUNEL reaction mixture. As a positive control, cells were treated
with recombinant DNase I. Images were taken at 200 x magnification. No differences in
degradation of DNA among untransfected HSC (Con), HSC transfected with siEng or
HSC transfected with siCon were determined using the TUNEL assay. Degradation of
DNA is one parameter of apoptosis. These results confirmed that cells transfected with
siEng are viable (not apoptotic).
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Figure 3.4: siRNA mediated silencing of endoglin in HSC. HSC were transfected with
siRNA on day 1. Silencing of endoglin on the level of protein was analyzed by (a) Western blot-
ting at the indicated time points. 20 µg protein were loaded onto a 4-12% Bis-Tris gel. Silencing
of endoglin on the level of mRNA was examined either by (b) comparative RT-PCR or by (c)
Northern blot analysis. mRNA for comparative RT-PCR was isolated from HSC harvested on
day 8 and reverse transcribed to cDNA. mRNA for Northern blot analysis was isolated from
HSC harvested on day 8. For Northern blot analysis 5 µg of total RNA were loaded onto a
formaldehyde agarose gel. (a) HSP70, (b) rS6 and (c) GAPDH were used as loading controls.
(d) HSC were seeded on glass slides and transfected with siRNA on day 1. On day 8 HSC were
fixed with 4% PFA and incubated with the TUNEL reaction mixture. As a positive control, HSC
were treated with recombinant DNase I. Images were taken at 200 x magnification. (a, b, c, d)
Untransfected HSC (Con) and HSC transfected with scrambled siRNA (siCon) were used as
negative controls. Protein (a) and nucleic acid (b, c) standard size markers are indicated in the
left margin.
Treatment of HSC resulted in a very strong and sustained knock down of endoglin on the level
of mRNA as well as on the level of protein. Furthermore, siRNA treatment did not induce
apoptosis.
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3.2 Characterization of endoglin deficient HSC
The use of siRNA oligonucleotides resulted in a very efficient and sustained knock
down of endoglin in HSC. This knock down provides a stable basis to analyze the ef-
fects of a reduced endoglin expression on activation and transdifferentiation of HSC.
3.2.1 Morphology and ECM abundance
HSC start to transdifferentiate into myofibroblast-like cells as soon as they are seeded
on tissue culture dishes. This transdifferentiation is associated with changes in cellular
morphology, with the loss of lipid droplets and with the development of cell-cell con-
tacts. Therefore, morphological features of HSC transfected with siEng were analyzed.
Transfection of HSC on day 1 of culture
HSC were transfected with siRNA on day 1. Morphology of HSC during transdiffer-
entiation was analyzed using bright field microscopy (a). Images were taken on the
days 4, 5 and 6 (Fig. 3.5 a) as well as on the days 7, 8 and 9 (Fig. 3.6 a). Untrans-
fected HSC (Con) and HSC transfected with scrambled siRNA (siCon) were used as
negative controls. Bright field microscopy revealed alterations in morphology during
transdifferentiation. Although HSC were transfected on day 1, which leads to a maxi-
mal down-regulation of endoglin on day 3, these alterations became first visible on day
5. Morphological transdifferentiation is accompanied by a loss of lipid droplets and the
development of cell-cell contacts. Transfection of HSC with siEng led to an inhibition of
this morphological transdifferentiation (Fig. 3.5 a and Fig. 3.6 a). HSC transfected with
siEng did not lose their circular arranged lipid droplets and form less or no cellular
contacts to their neighbor cells.
Beside changes in cellular morphology (morphological transdifferentiation), trans-
differentiation is also accompanied by specific up-regulation of ECM genes and by up-
regulation of α-SMA. Therefore, the quantity of ECM components and of α-SMA as a
marker of transdifferentiation, was analyzed. Western blot analysis of HSC transfected
with siRNA on day 1 was performed (Fig. 3.5 b and Fig. 3.6 b). Antibodies specific
for ECM components and for α-SMA were used. Western blot analysis of HSC trans-
fected with siEng showed a reduced amount of collagen type I, collagen type IV, and
fibronectin when compared to control cells. The reduced amount of collagen type I
became visible on day 5 and remained decreased at least until day 9. Even though
collagen type I is not completely abolished, the total amount of collagen type I is sig-
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Figure 3.5: Morphology and ECM expression of HSC on the days 4, 5 and 6 of culture.
HSC were transfected with siRNA on day 1. At indicated time points the morphology was
analyzed by (a) bright field microscopy (200 x magnification) and protein lysates were analyzed
by (b) Western blotting. For Western blot analysis 20 µg or 5 µg protein were loaded onto
a 4-12% Bis-Tris gel in order to analyze the expression of endoglin and α-SMA, respectively.
Additionally, 10 µg protein were loaded onto a 3-8% Tris-Acetate gel in order to analyze the
expression of ECM components. Untransfected HSC (Con) and HSC transfected with scrambled
siRNA (siCon) were used as negative controls. S6 and β-Actin were used as loading controls.
Protein standard size markers are indicated in the left margin.
Western blot analysis revealed a reduced amount of ECM components. In contrast, the expres-
sion of the transdifferentiation marker α-SMA is unaffected.
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Figure 3.6: Morphology and ECM expression of HSC on the days 7, 8 and 9 of culture.
HSC were transfected with siRNA on day 1. At indicated time points the morphology was
analyzed by (a) bright field microscopy (200 x magnification) and protein lysates were analyzed
by (b) Western blotting. For Western blot analysis 20 µg or 5 µg protein were loaded onto
a 4-12% Bis-Tris gel in order to analyze the expression of endoglin and α-SMA, respectively.
Additionally, 10 µg protein were loaded onto a 3-8% Tris-Acetate gel in order to analyze the
expression of ECM components. Untransfected HSC (Con) and HSC transfected with scrambled
siRNA (siCon) were used as negative controls. S6 and β-Actin were used as loading controls.
Protein standard size markers are indicated in the left margin.
Microscopy revealed an inhibition of morphological transdifferentiation of HSC transfected
with siEng. Western blot analysis revealed a reduced amount of ECM components such as
collagen type I, type IV and fibronectin. Furthermore, silencing of endoglin was confirmed by
Western blot analysis.
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nificantly reduced compared to untransfected HSC (Con) and HSC transfected with
siCon. Reduction in collagen type IV and fibronectin expression became visible on day
7. α-SMA, as a marker of HSC activation and trandifferentiation remained unaffected
in HSC transfected with siEng compared to untransfected HSC (Con) and HSC trans-
fected with siCon.
Therefore, the overall tendency to transdifferentiate was reduced as indicated by
two observations: 1. The inhibition of morphological transdifferentiation and 2. the
reduced amount of ECM components.
Transfection of HSC on day 3, 4 and 5 of culture
Transfection of HSC with siEng on day 1 of culturing led to an inhibiton of transdiffer-
entiation. This raises the question, if silencing of endoglin at later time points produce
comparable effects? This is questionable, because at later time points the morphologi-
cal transdifferentiation and collagen type I expression are already ongoing. Therefore,
endoglin was silenced and analyzed at later time points of the transdifferentiation pro-
cess.
In order to analyze these parameters, HSC were transfected with siRNA on day 3
(Fig. 3.7 a, d), day 4 (Fig. 3.7 b, e) and day 5 (Fig. 3.7 c, f). Bright field microscopy (Fig.
3.7 a, b, c) and Western blot analysis (Fig. 3.7 d, e, f) were performed on day 7, day 8 and
day 9. Bright field microscopy revealed an inhibition in morphological transdifferenti-
ation of HSC, which were transfected with siEng either on day 3 or on day 4. However,
these differences were less in HSC transfected on day 4 compared to HSC transfected
on day 3. Images of HSC transfected with siEng on day 5 were almost identical to the
images of the corresponding controls. Western blot analysis revealed a very efficient
down-regulation of endoglin in HSC transfected either on day 3 (Fig. 3.7 d), day 4 (Fig.
3.7 e) or day 5 (Fig. 3.7 f). As one representative of ECM components the quantity of
collagen type I in HSC on day 7, day 8 and day 9 was analyzed by Western blotting.
Transfection of HSC on day 3, on day 4 and on day 5 caused a reduction of collagen
type I at each time point analyzed. However, changes in collagen type I abundance
were less in HSC transfected on day 5, thus reconfirming the results observed in bright
field microscopy.
3.2.2 Cytoskeleton organization
As the lack of endoglin caused alterations of the cellular morphology during transdif-
ferentiation, the organization of the cytoskeleton of HSC was analyzed next.
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Figure 3.7: Endoglin silencing on day 3, day 4 and day 5 of culture. Bright field mi-
croscopy (a, b, c) and Western blot analysis (d, e, f) of HSC transfected with siRNA on day 3,
on day 4 and on day 5. HSC were isolated, seeded on 6-well plates and transfected with siRNA
either on day 3 (a, c), on day 4 (b, e) or on day 5 (c, f). Images were taken (200 x magnification)
and protein lysates of HSC harvested on day 7, on day 8 and on day 9 were analyzed. 10 µg
protein were loaded onto a 3-8% Tris-Acetate gel and analyzed using a specific antibody di-
rected against collagen type I. To demonstrate endoglin down-regulation 20 µg of protein were
loaded onto a 4-12% Bis-Tris gel and analyzed using a specific antibody directed against en-
doglin. β-Actin was used as a loading control. Protein standard size markers are indicated in
the left margin. Untransfected HSC (Con) and HSC transfected with scrambled siRNA (siCon)
were used as negative controls. Abbreviations: Col I, collagen type I; Eng, endoglin
Morphological transdifferentiation was significantly inhibited when HSC were transfected with
siEng either on day 3 or on day 4. In contrast, transfection of HSC with siEng on day 5 resulted
in less significant changes in morphological transdifferentiation. Furthermore, the amount of
collagen type I is slightly reduced in HSC transfected with siEng at each time point analyzed.
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HSC were isolated, seeded either on tissue culture dishes (Fig. 3.8 a, b, f, g and
Fig. 3.9) or on glass slides (Fig. 3.8 c, d and e) and transfected with siRNA on day 1.
To investigate the organization of the cytoskeleton F-actin was stained with phalloidin
that directly binds to actin fibres. In addition the LIM domain protein CRP2 was over-
expressed. It has been shown that CRP2 binds to the actin fibres and may be an indirect
interaction partner for endoglin. Therefore, HSC were partially infected on day 6 with
either an adenovirus overexpressing CRP2 or with an adenovirus overexpressing the
CRP2-GFP fusion protein. On day 8 cells were fixed with 4% of PFA. Bright field mi-
croscopy was performed (Fig. 3.8 a) and images of the autofluorescence of HSC were
taken under UV-light (Fig. 3.8 b). F-actin of uninfected HSC (Fig. 3.8 c) and of HSC
infected with an adenovirus overexpressing the untagged version of CRP2 (Fig. 3.8 e)
were stained with phalloidin. Images of HSC infected with the adenovirus CRP2-GFP
were taken under UV-light (Fig. 3.8 d). Nuclei were counterstained with DAPI.
Images obtained by bright field microscopy and by autofluorescence reconfirmed
the inhibition of morphological transdifferentiation. HSC transfected with siEng did
not lose their circular arranged lipid droplets (Fig. 3.8 a and b). Furthermore, HSC
transfected with siEng showed differences in the phalloidin staining pattern compared
to untransfected HSC (Con) and HSC transfected with scrambled siRNA (siCon) (Fig.
3.8 c). HSC transfected with siEng revealed a lack of parallel actin-fibers and a more
pronounced radial staining at the edge of the cells. Control cells showed a staining
pattern with parallel bundles of F-actin all over the cell. In order to analyze the al-
terations observed in phalloidin stained HSC in more detail HSC were infected with
an adenovirus overexpressing a GFP-tagged version of CRP2. HSC transfected with
siEng revealed a different CRP2-GFP staining pattern compared to HSC transfected
with siCon and untransfected HSC (Con). In HSC transfected with siEng a discontinu-
ous staining pattern with marked spots at the ends of short fiber structures and a faint
stain at the edge of the cell (Fig. 3.8 d) were observed. To rule out the possibility that
these effects were due to the GFP-tag, HSC were first infected with a virus overexpress-
ing an untagged version of CRP2 and afterwards HSC were stained using phalloidin.
Phalloidin staining revealed differences in the organization of the cellular actin skeleton
between HSC transfected with siEng and the corresponding controls (Fig. 3.8 e). HSC
transfected with siEng showed a discontinuous staining pattern with accumulation of
F-actin at different positions within the cell.
The staining pattern of untransfected HSC (Con) and HSC transfected with scram-
bled siRNA (siCon) were comparable within all staining procedures (phalloidin, CRP2-
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Figure 3.8: Organization of the cytoskeleton and mRNA expression of proteins associ-
ated with endoglin. HSC were transfected with siRNA on day 1 (a-e) and partially infected
on day 6 with an adenovirus overexpressing either CRP2-GFP (d) or CRP2 (e). On day 8 cells
were fixed in 4% PFA, stained and images were taken (400 x magnification). Cells overexpress-
ing CRP2 were stained with phalloidin. Nuclei were counterstained with DAPI. Untransfected
HSC (Con) and HSC transfected with scrambled siRNA (siCon) were used as negative con-
trols. The morphology and autofluorescence of HSC were analyzed (a, b). The formation of
the cytoskeleton was analyzed (c, d, e) using phalloidin and CRP2-GFP. Comparative RT-PCR
was performed in order to demonstrate the expression of Zyxin (523 bp) and ZRP-1 (520 bp)
in HSC (F). For comparative RT-PCR mRNA was isolated from HSC harvested on day 8 and
reverse transcribed to cDNA. S6 was used as a loading control. Molecular weight markers are
indicated in the left margin.
The appearance of circular arranged lipid droplets supports the finding that transdifferentiation
is inhibited. Additionally, endoglin silencing resulted in a re-arrangement of the cytoskeleton
and to a relocalization of CRP2.
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Figure 3.9: Silencing of endoglin results in a re-arrangement of the cytoskeleton. For bet-
ter visualization enlarged images (400 x magnification) of HSC lacking endoglin are presented
once again (additional to Fig. 3.8 c, d, e). (a) Image of phalloidin stained HSC. (b) Image of
the CRP2-GFP fluorescence pattern of HSC. (c) Image of phalloidin stained HSC, which were
overexpressing CRP2.
GFP, CRP2 phalloidin). All control cells showed a staining pattern with parallel bun-
dles of F-actin all over the cell. In contrast, silencing of endoglin led to different stain-
ing pattern with respect to all three staining procedures (phalloidin, CRP2-GFP, CRP2
phalloidin). For a better visualization, images are enlarged presented in Fig. 3.9. These
images exclusively show the staining pattern of HSC transfected with siEng. There-
fore, the actin cytoskeleton and the CRP2 localization are changed in the absence of
endoglin.
Zyxin has been shown to regulate migration of endothelial cells by influencing the
organization of the cytoskeleton. Furthermore, it was shown that this effect was me-
diated by an interaction of Zyxin with endoglin [51]. ZRP-1 (zyxin related protein-1)
shows high similarities to Zyxin [124] and it has been shown that endoglin regulates
the organization of the cytoskeleton by binding to ZRP-1 [52]. Since at least Zyxin di-
rectly binds CRP2, the localization of CRP2 and the organization of the cytoskeleton
might be governed by an indirect interaction of CRP2 and endoglin, which in turn
might be mediated by Zyxin and/or ZRP-1. Therefore, Zyxin as well as ZRP-1 might
be the missing links between the observed alterations of the cytoskeleton and endoglin
down-regulation. In order to substantiate the hypothesis that Zyxin and ZRP-1 are an
important component for the organization of the cytoskeleton, mRNA expression of
Zyxin and ZRP-1 in HSC was confirmed by RT-PCR. Furthermore, RT-PCR revealed an
endoglin independent expression of Zyxin and ZRP-1 in cultured HSC (Fig. 3.8 f and
g).
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3.2.3 Migration
It is assumed that HSC in vivo have the potential to migrate towards the inflammatory
regions in order to participate in the wound healing process. Comparable to HSC in
vivo, HSC in vitro have the potential to migrate on tissue culture plates towards a spot
with a low number of HSC. To analyze the impact of endoglin silencing on HSC migra-
tion, a wound healing assay was performed. HSC were isolated and plated onto tissue
culture plates. On day 1 HSC were transfected with siRNA. On day 2 a 100 µl tip was
used to make a scratch as shown in Fig. 3.10. Subsequent floating cells were removed
by washing twice with DMEM containing 10% FCS. In order to follow the movement
of the cells, images were taken using bright field microscopy. In figure 3.10 represen-
tative images of day 2, day 8 and day 14 are presented. Untransfected HSC (Con) and
HSC transfected with scrambled siRNA (siCon) were used as negative controls. This
assay revealed no significant differences in migration of HSC transfected with siEng
compared to the corresponding controls.
Con
2d
8d
14d
siEng siCon
Figure 3.10: Migration of HSC. On day 1 HSC were transfected with siRNA. One day later a
100 µl tip was used to make a scratch. Bright field microscopy was used to analyze the migration
of HSC. Representative bright field images of day 1, day 7 and day 13 are shown.
Migration of HSC was evident, but no differences in the migration pattern of HSC transfected
with siEng, siCon or untransfected HSC were observed.
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3.2.4 Proliferation
Another feature of HSC during transdifferentiation is an increase in cell proliferation.
One method to determine cell proliferation is the measurement of 3H-thymidine incor-
poration. This method has been the traditional method for detection of cell proliferation
for a long time and is known as very sensitive. However, the handling and disposal of
radioisotopes as well as the incorporation of 3H-thymidine as a result of DNA repair are
the main disadvantages. This is worth of mention, because HSC exhibit an increased
cell repair. An alternative to 3H-thymidine proliferation assay is the BrdU prolifera-
tion assay. In these methods bromodeoxyuridine (BrdU) is incorporated into newly
synthesized DNA strands of proliferating cells. This assay is free of radioisotopes and
excludes incorporation through cell repair processes, but compared to 3H-thymidine
the BrdU assay is not as sensitive. However, to analyze the impact of endoglin si-
lencing on cell proliferation both proliferation assays - 3H-thymidine and BrdU - were
performed. HSC were isolated and transfected with siRNA on day 1. Depending on
the assay HSC were either exposed to 3H-thymidine on day 3 for a time period of 24 h
or exposed to BrdU on day 4 for a time period of 48 h. Untransfected HSC (Con) and
HSC transfected with scrambled siRNA (siCon) were used as negative controls. The
BrdU assay (Fig:. 3.11 a) revealed an inhibition of cell proliferation for HSC transfected
with siEng. The inhibition of proliferation is approx. 30% compared to untransfected
HSC (Con) and HSC transfected with siCon. Proliferation of untransfected HSC (Con)
and HSC transfected with scrambled siRNA (siCon) was equal. Comparable to BrdU
the 3H-thymidine assay (Fig:. 3.11 b) revealed an inhibition of proliferation for HSC
transfected with siEng. The inhibition of proliferation for HSC transfected with siEng
is approx. 50% compared to untransfected HSC (Con) and approx. 30% compared to
HSC transfected with siCon.
Statistical analysis was performed with an unpaired Student’s t-test for both incor-
poration assays. The BrdU assay revealed p = 0.00043 for HSC transfected with siEng
compared to untransfected HSC (Con) and p = 0.003 for HSC transfected with siEng
compared to HSC transfected with siCon. The 3H-thymidine assay revealed p = 0.00002
for HSC transfected with siEng compared to untransfected HSC (Con) and p = 0.0002
for HSC transfected with siEng compared to HSC transfected with siCon. Therefore,
both assays revealed highly significant differences (≤ 0.01) in cell proliferation between
HSC transfected with siEng and the respective controls.
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Figure 3.11: BrdU and 3H-thymidine proliferation assays. HSC were transfected with
siRNA on day 1. (a) On day 4 HSC were treated with BrdU and incorporation of BrdU was
determined 48 h later by measuring the OD450 per well. (b) On day 3 HSC were treated with
3H-thymidine and incorporated radioactivity was measured 24 h later. Statistical analysis was
performed for both incorporation assays with an unpaired Student’s t-test. Significant differ-
ences (≤ 0.01) are indicated by asterisks.
In both proliferation assays HSC transfected with siEng proliferate less than the respective con-
trols.
3.2.5 Whole genome microarray
To further analyze the molecular background of the disturbed transdifferentiation in
HSC lacking endoglin an Agilent whole-genome microarray was performed. This ar-
ray comprises the expression of more than 41000 rat genes. Sample preparation, RNA
isolation and final data analysis were accomplished as part of this thesis. Quality check,
RNA amplification, hybridization and raw data analysis were processed by Miltenyi
Biotec GmbH.
RNA isolation and quality check
A total number of 8 animals were sacrificed and subsequent 8 independent HSC isola-
tions, transfections and sample preparations were performed. As described in materials
and methods, HSC were transfected with siRNA on day 1. Total RNA was isolated on
day 8, cDNA was synthesized using 1 µg of total RNA and silencing of endoglin was
analyzed by comparative RT-PCR (Fig. 3.12 a). RT-PCR revealed a significant reduction
of endoglin mRNA in all RNA samples obtained from HSC transfected with siEng. A
specific transcript for the ribosomal S6 protein was used as loading control. Out of the
initial 8 groups 4 groups were used for microarray analysis and were analyzed at Mil-
tenyi. Putative RNA degradation was analyzed by Miltenyi using a Bioanalyzer. The
results were visualized in a gel image (Fig. 3.12 b) and in an electropherogram (Fig.
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3.12 c). The RIN (RNA Integrity Number) was calculated and revealed a RIN of 10 for
all samples. A RIN number of 10 indicates perfect, not degraded RNA. Therefore, all
samples were suitable for microarray analysis. One group (out of four groups) was in-
dependently processed (single). The corresponding samples (Con, siEng, siCon) of the
remaining three groups were pooled and further processed as one group (pool). Each
group consisted of untransfected HSC (Con), HSC transfected with siEng (siEng) and
HSC transfected with siCon (siCon).
Four sets of hybridization were performed. Hybridization no. 1 (single) and no. 3
(pool) were performed to identify genes, which were differentially expressed caused
by the transfection procedure. Within hybridization no. 1 and within hybridization
no. 3 the expression profiles of untransfected HSC (Con) and HSC transfected with
siCon were compared. Hybridization no. 2 (single) and no. 4 (pool) were performed to
identify genes, which are differentially expressed caused by endoglin down-regulation.
Within hybridization no. 2 and within hybridization no. 4 the expression profiles of
HSC transfected with siEng and HSC transfected with siCon were compared. Details
of the hybridization scheme are described in detail in chapter 2.21.2.
Results of the whole genome microarray
The data output received from Miltenyi included the complete raw data sets as well
as one list for each hybridization containing the differentially expressed genes. Genes
are defined as differentially expressed when they show a fold change ≥ 2 and p-value
≤ 0.01. The complete raw data sets were deposited in the Gene Expression Omnibus
(GEO) repository. The accession numbers are GSM256740 for hybridization no. 1, GSM-
256756 for hybridization no. 2, GSM256757 for hybridization no. 3 and GSM256758 for
hybridization no. 4. In contrast to the raw data, the lists of differentially expressed
genes were processed as follows. Genes, which were differentially expressed caused
by the transfection procedure (Gene lists 1 and 3), were removed from gene lists 2 and
4. To further select genes differentially expressed caused by endoglin down-regulation,
the intersection of gene lists 2 and 4 was formed. In this way genes, which were not
listed in both hybridizations, were skipped. The remaining genes form a group of se-
lected candidate genes and are listed in Appendix A. 44 genes listed in Appendix A are
up regulated and 64 genes are down regulated. Genes listed in Appendix A were fur-
ther analyzed regarding their function. Genes, which might be linked to the observed
cellular alterations, were manually chosen and are presented in figure 3.13. Some of
these genes have been linked to TGFβ-1 and/or BMP-7 signaling (e.g. Ltbp2, Noggin,
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Figure 3.12: RNA quality check. HSC were transfected with siRNA on day 1 and total RNA
was isolated on day 8. 1 µg of total RNA was reverse transcribed into cDNA in order to perform
comparative RT-PCR. (a) Endoglin silencing was analyzed by RT-PCR. S6 was used as a loading
control. Total RNA degradation was analyzed by Miltenyi and visualized in (b) a gel image and
in (c) an electropherogram. (b) The gel image showed exclusively the 18S and the 28S RNA
band and an internal standard (green band). RNA standard size marker is indicated in the left
margin. (c) The electropherogram showed only two prominent peaks, the 18S RNA and 28S
RNA.
Endoglin mRNA was significantly reduced in RNA samples obtained from HSC transfected
with siEng. No degradation was detected. All samples obtained a RIN of 10, thus, being suitable
for microarray analysis.
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ALK1), matrix assembly and turnover (e.g. α2M, MMP10, Cthrc1) and differentiation
of endothelial cells (e.g. Edg7). The eye-catcher of this array was α2-macroglobulin. In
HSC lacking endoglin α2-macroglobulin showed a fold change of about 14 in its expres-
sion (”single” microarray). In comparison endoglin showed a fold change of only 8 in
the same hybridization.
Northern blot analysis for endoglin, α2-macroglobulin, collagen type I and fibro-
nectin was performed in order to reconfirm the results of the microarray analysis.
GAPDH was used as a loading control (Fig. 3.13 b). 5 µg of total RNA was loaded onto
the gel. Northern blot analysis reconfirmed the results obtained by microarray analysis.
This includes the efficient down-regulation of endoglin as an internal control and the
efficient down-regulation of α2-macroglobulin. Furthermore, Northern blot analysis
revealed no differences in mRNA expression of collagen type I and fibronectin.
Abbreviations and gene symbols used in Fig. 3.13 are α2M, α2-macroglobulin; Wisp1,
WNT1-inducible signaling pathway protein; Eng, endoglin; Ptgis, Prostaglandin I2
synthase; Vil, villin; Cthrc1, collagen triple-helix repeat-containing protein 1; PapIn,
Plakophilin-related armadillo repeat protein-interacting PDGZ protein; Mfap4, micro-
fibril-associated protein 4; Rgs5, regulator of G protein signaling 5; Ltbp2, latent trans-
forming growth factor-β-binding protein 2; Acvrl1, activin A receptor type II-like1;
Sfrp1, secreted frizzled-related protein 1; Laminin α-4 chain, laminin alpha 4 chain;
Mfap5, microfibrillar associated protein 5; Rgn, regucalcin; NCAML1, Rattus norvegi-
cus L1 cell adhesion molecule; Tm4sf1, tumor-associated antigen L6; K1CJ, Keratin,
type I cytoskeletal 10; Nog, noggin; Kdr, tyrosine kinase growth factor receptor; MMP10,
matrixmetalloproteinase 10, Cxcl2, chemokine (CXC motif) ligand 2; Edg7, endothelial
differentiation gene 7; Nppc, natriuretic peptide precursor C.
Gene classification
Most of the differentially expressed genes, which are listed in Appendix A, are already
well characterized. They are associated with different cellular features and processes.
To determine the cellular feature, to which these genes belong to, a pathway analysis
was performed by Miltenyi. Eight groups were distinguished, i.e. structural, stress,
signaling mechanism, signaling, organismal, metabolism, cellular process, cellular be-
havior. These groups were further divided into subgroups. Genes listed in Appendix
A and their corresponding proteins, respectively were allocated to one of these groups.
Unless no information about the gene or protein was available. Double allocations
were possible. Finally, a classification scheme as shown in figure 3.14 was received.
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Figure 3.13: A list of selected microarray genes and their verification by Northern blot
analysis. (a) A selection of 24 differentially expressed genes are listed in the diagram. These
genes were chosen because their expression was strongly modified or their corresponding pro-
teins might be jointly responsible for the cellular alterations, which were observed in HSC trans-
fected with siEng. Endoglin, as an internal control is 8.3 fold down regulated in hybridization
no. 2 (single sample) and 3.5 fold down regulated in hybrdidization no. 4 (pool). The x-axis indi-
cates the fold change in gene expression. (b) Northern blot analysis was performed to verify the
result of the microarray for endoglin, α2-macroglobulin, collagen type I (Col I) and fibronectin
(Fn). mRNA for Northern blot analysis was isolated from HSC, which were harvested on day
8. 5 µg of total RNA were loaded onto a formaldehyde agarose gel. GAPDH was used as a
loading control. Abbreviations and gene symbols are described in the body text.
Northern blot analysis reconfirmed the results of the microarray for endoglin, α2-
macroglobulin, collagen type I and fibronectin.
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In this scheme more than 110 differentially expressed genes and their corresponding
proteins are associated with receptor signaling, followed by around 90 differentially
expressed genes and their corresponding proteins, which are associated with develop-
ment. Around 60 genes and their corresponding proteins are associated with cellular
import and export. Furthermore, around 60 genes and their corresponding proteins are
associated with cell differentiation. Except for these four subgroups (receptor signal-
ing, development, cellular import and export, differentiation) the number of genes in
the remaining subgroups were not above average.
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Figure 3.14: Classification of the differentially expressed genes (siEng vs. siCon) and
their corresponding proteins into subgroups of cellular features. 8 groups and in total
38 subgroups are distinguished. X-axis: number of genes belonging to the indicated subgroup
(Y-axis).
Most of the differentially expressed genes and their corresponding proteins were allocated to
receptor signaling, followed by development and cellular import/export as well as cell differ-
entiation. The number of genes in the remaining subgroups were not above average.
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3.2.6 Summary: Characterization of endoglin deficient HSC
Before completing this section, results are summarized in figure 3.15.
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Figure 3.15: Transdifferentiation of control HSC vs. HSC transfected with siEng. Chan-
ges of different cell features, which were caused by endoglin silencing, are described in this
image. Blue arrows describe the changes in control cells and red arrows describe the changes
in HSC transfected with siEng on day 1. X-axis: day of culture; Y-axis: attributes, which are
modified during transdifferentiation.
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3.3 α2-Macroglobulin
In consequence of endoglin silencing α2-macroglobulin expression was mostly affected
as revealed in the cDNA microarray. This result was reconfirmed by Northern blot
analysis. α2-Macroglobulin is known as a marker of transdifferentiation and as an in-
hibitor of matrix metalloproteinases. Therefore, it is likely that α2-macroglobulin might
act down stream of endoglin thus being involved in the observed cellular alterations.
3.3.1 α2-Macroglobulin down-regulation through endoglin silencing
As an inhibitor of metalloproteinases α2-macroglobulin is involved in degradation of
ECM components. Therefore, down-regulation of α2-macroglobulin might result in an
increased MMP activity and this in turn might result in an increased degradation of
ECM components, such as collagen type I, IV and fibronectin. This hypothesis might
explain the results obtained by Western blot analysis (Fig. 3.5, 3.6 and Fig. 3.7). Due
to these facts α2-macroglobulin was investigated in more detail. First of all down-
regulation of α2-macroglobulin in HSC lacking endoglin was additionally analyzed by
Western blotting. The antibody, which was used to detect α2-macroglobulin, was raised
against human α2-macroglobulin. HSC were either transfected with siRNA on day 1
(Fig. 3.16 a) and cell lysates were analyzed on days 4, 5, 6, 7, 8 and 9 or transfected on
day 3 (Fig. 3.16 b), on day 4 (Fig. 3.16 c) and on day 5 (Fig. 3.16 d) and cell lysates were
analyzed on days 7, 8 and 9. HSP70 and PonceauS were used as loading controls. In cell
lysates of HSC transfected on day 1 the amount of α2-macroglobulin was significantly
reduced at all time points analyzed. The corresponding controls revealed an increase
in α2-macroglobulin expression starting on day 4. Transfection of HSC with siEng at
later time points did also result in a significant decrease of α2-macroglobulin. Further-
more, a time delay in α2-macroglobulin down-regulation as a consequence of endoglin
down-regulation became obvious in figure 3.16 d. Cell lysates analyzed in figure 3.16 d
were obtained from HSC transfected with siRNA on day 5. Transfection of HSC on day
5 led to a maximal endoglin knock down on day 7. At this time point α2-macroglobulin
is still detectable, but on day 8 α2-macroglobulin is significantly decreased. Therefore,
down-regulation of endoglin is followed by α2-macroglobulin down-regulation with a
time delay of 24 h.
Using Western blot analysis it could be demonstrated that α2-macroglobulin is less
abundant in HSC lacking endoglin. However, the observed reduction is not as strong as
expected. One explanation might be the extracellular localization of α2-macroglobulin.
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Figure 3.16: Western blot analysis of α2-macroglobulin in HSC transfected with either
scrambled siRNA or with siRNA targeting endoglin. HSC were transfected with siRNA on
day 1 (a), on day 3 (b), on day 4 (c) or on day 5 (d). HSC were analyzed by Western blotting using
cell lysates of HSC harvested at the indicated time points. 20 µg of protein were loaded onto
a 3-8% Tris-Acetate gel and α2-macroglobulin was detected with an antibody specific for α2-
macroglobulin. HSP70 and PonceauS were used as loading controls. Untransfected HSC (Con)
and HSC transfected with scrambled siRNA (siCon) were used as negative controls. Protein
standard size markers are indicated in the left margin.
α2-macroglobulin was down regulated in HSC transfected with siEng at all time points ana-
lyzed. Only exception, HSC transfected on day 7.
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Therefore, the amount of α2-macroglobulin in the culture medium of cultured HSC was
verified by Western blot analysis. However, specific detection of rat α2-macroglobulin
in the conditioned cell supernatant was not possible. FCS as a supplement of the cell
culture medium contains a high amount of calf α2-macroglobulin. The antibody, which
was used to detect rat α2-macroglobulin, did cross reacts with calf α2-macroglobulin.
Thus, it was not possible to distinguish between rat α2-macroglobulin and calf α2-
macroglobulin.
3.3.2 Gelatinase and collagenase assay
As already mentioned α2-macroglobulin is known as an inhibitor of matrix metallopro-
teinases. To proof whether α2-macroglobulin down-regulation leads to an increase in
matrix metalloproteinase activity, a gelatinase assay was performed. To test the func-
tionality of this assay, especially under cell culture conditions, a control assay was per-
formed as shown in figure 3.17 a. HSC were cultured in 96-well plates and DMEM
containing 10% FCS. One day after initial plating, cells were transfected with siRNA.
On day 4 the gelatinase assay was initiated and the fluorescence was measured at the
indicated time points. Clostridium collagenase was applied in different concentrations
(0.005 U/ml, 0.025 U/ml, 0.05 U/ml) to a mixture of fluorescein-labeled DQ gelatin con-
jugate and reaction medium. This medium was either 1 x reaction buffer (a component
of the EnzChek Gelatinase/Collagenase Assay Kit), H2O or DMEM containing either
10% FCS or containing 0.1% BSA, penicillin, streptomycin and L-glutamine. Fluores-
cence was measured in a fluorescence microplate reader equipped with standard fluo-
rescein filters. It turned out that all reaction mediums are suitable. However, the test
revealed a reduced fluorescence when reaction buffer was replaced with DMEM con-
taining 10% FCS or 0.1% BSA. Based on this result gelatinase activity and collagenase
I activity of untransfected HSC (Con) and HSC transfected with siEng and siCon were
determined. For these experiments fluorescein-labeled DQ gelatin conjugate (Fig. 3.17
b) or fluorescein-labeled DQ collagen type I conjugate (Fig. 3.17 c) were added either
to conditioned medium (DMEM 10% FCS), to HSC cultivated in 10% FCS or cultivated
in DMEM 0.1% BSA or cultivated in reaction buffer. As a positive control Costridium
collagenase was additionally added to one sample. Fluorescence was measured at the
beginning of the experiment, after 24 h incubation and after 48 h incubation. Incubation
of HSC was performed at 37°C in a CO2 incubator with a concentration of 5% CO2 and
100% relative humidity. Even though fluorescence increased marginally during incuba-
tion, no differences between HSC transfected with siEng and controls were observed.
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Figure 3.17: Determination of the proteinase activity using the EnzChek gelatinase
and collagenase assay kit. HSC were cultured in 96-well plates and DMEM containing
10% FCS. One day after initial plating, cells were transfected with siRNA. On day 4 the gelati-
nase/collagenase assay was initiated and fluorescence was measured at 530 nm at the indicated
time points. (a) The functionality of this assay was initially tested using different buffers and
different concentrations of Clostridium collagenase (0.05 U/ml, 0.025 U/ml, 0.005 U/ml). (b)
Gelatinase activity of untransfected HSC (Con) and of HSC transfected with siEng or siCon
was measured. (c) Collagenase I activity of untransfected HSC (Con) and of HSC transfected
with siEng or siCon was measured. Clostridium collagenase was used as positive control.
No differences were detected between untransfected HSC (Con) and HSC transfected with
siEng or siCon.
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The positive control containing Clostridium collagenase showed a significant increase in
fluorescence. Therefore, it is likely that this assay is not suitable for this kind of experi-
ment. Otherwise it might be that collagenase I and gelatinase activity is not changed in
HSC transfected with siEng compared to the corresponding controls.
3.3.3 siRNA targeting α2-macroglobulin
Due to the fact that the inhibition of MMP activity is only one putative function of α2-
macroglobulin more experiments were performed. To analyze if α2-macroglobulin acts
down stream of endoglin, α2-macroglobulin was silenced. For this purpose siRNA di-
rectly targeting α2-macroglobulin mRNA was used. Similar to the evaluation of siEng
functionality the time and concentration dependent silencing effects of siα2M were
tested.
HSC were transfected with siRNA on day 3. siRNA was applied as a mixture of two
different siRNAs targeting α2-macroglobulin mRNA. The final concentration of siRNA
in the transfection mixture was 5 nM or 10 nM. Bright field microscopy (200 x magnifi-
cation) of HSC was performed on days 8 and 9 (Fig. 3.18 a) and showed an inhibition
of morphological transdifferentiation in HSC transfected with siα2M. The character of
inhibition is comparable to the inhibition obtained by transfection of HSC with siEng.
HSC transfected with either siEng or siα2M did not lose their circular arranged lipid
droplets. Furthermore, the development of cell-cell contacts seemed to be decreased.
Next the quantity of collagen type I and type IV was analyzed by Western blotting using
protein lysates of HSC, which were harvested on day 8 (Fig. 3.18 b). Western blot anal-
ysis showed equal amounts of collagen type I and type IV. However, down-regulation
of α2-macroglobulin was confirmed using an antibody specifically raised against rat α2-
macroglobulin. Therefore, it is likely that silencing of α2-macroglobulin inhibits mor-
phological transdifferentiation, but has no impact on the quantity of collagen type I and
type IV.
Functional characterization of α2-macroglobulin just started with these experiments.
To further support the hypothesis that α2-macroglobulin acts down stream of endoglin
more experiments need to be done. However, inhibition of morphological transdiffer-
entiation is already the first hint.
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Figure 3.18: Effect of α2-macroglobulin down-regulation on morphology and ECM ex-
pression in HSC. HSC were transfected with siRNA on day 3. Two concentrations of siRNA
targeting α2-macroglobulin were used (5 nM, 10 nM). (a) Images were taken on day 8 and on
day 9. (b) HSC were analyzed by Western blotting using cell lysate of HSC harvested on day 8.
20 µg of protein were loaded onto a 3-8% Tris-Acetate gel. α2-macroglobulin expression, as well
as collagen type I and type IV expression were determined using specific antibodies. Untrans-
fected HSC (Con) and HSC transfected with scrambled siRNA (siCon) were used as negative
controls. Protein standard size markers are indicated in the left margin. β-Actin was used as a
loading control.
Silencing of α2-macroglobulin using siRNA directly targeting α2-macroglobulin was confirmed.
Silencing of α2-macroglobulin resulted in an inhibition of morphological transdifferentiation. In
contrast the amount of collagen type I and type IV remained unaffected.
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3.4 Stimulation Assays
Endoglin binds and modulates cellular responses of a broad range of TGF-β super-
family members. To analyze the impact of endoglin directly on the TGF-β and the
BMP pathways stimulation assays were performed. Beside Western blot analysis the
(CAGA)12MLP-luciferase construct and the (BRE)2-luciferase construct were used as a
read out system for these cytokines. The main idea of these reporter gene constructs is
an individual promoter region followed by a DNA sequence, which encodes the fire-
fly luciferase. Phosphorylated Smad3 specifically binds to the CAGA promoter region
and phosphorylated Smad1 specifically binds to the BRE promoter region. As a conse-
quence to binding the expression of luciferase is induced. Due to the fact that primary
HSC are very difficult to transfect, but easy to infect a (CAGA)12MLP-luciferase virus
and a (BRE)2-luciferase virus were generated.
3.4.1 TGF-β1 and BMP-7 stimulation experiments
The (CAGA)12MLP-luciferase virus and the (BRE)2-luciferase virus were generated,
amplified and purified as described in material and methods. Prior to amplification the
functionality of these viruses were tested in stimulation experiments using HSC (data
not shown). After amplification and purification the optimal virus concentration to in-
fect HSC and to perform stimulation experiments was tested (Fig. 3.19 a and b). In the
afternoon (approx. 4 p.m.) of day 2 HSC were infected with different concentrations of
either (CAGA)12MLP-luciferase virus or (BRE)2-luciferase virus. The next morning (ap-
prox. 10 a.m.)the medium was renewed using DMEM 10% FCS and again replaced for
starvation with DMEM 0.5% FCS in the late afternoon (approx. 4 p.m.). After approxi-
mately 16 h of starvation HSC were stimulated with either 1 ng/ml TGF-β1 or 50 ng/ml
BMP-7. After stimulation for a time period of 8 h HSC were harvested and luciferase
activity was measured. The test revealed an optimal concentration of 2 · 108 Pfu/ml for
(CAGA)12MLP-luciferase virus and an optimal concentration of ≥ 3 · 108 Pfu/ml for
(BRE)2-luciferase virus. Furthermore, the specificity of (CAGA)12MLP-luciferase for
TGF-β and the specificity of (BRE)2-luciferase for BMP-7 was reconfirmed.
Subsequently, the impact of endoglin on the TGF-β (Fig. 3.20 a and c) and the BMP-
7 pathways (Fig. 3.20 b) was analyzed. HSC were transfected with siRNA on day
1. For reporter gene assay HSC were additionally infected on day 2 with either the
(CAGA)12MLP-luciferase virus or the (BRE)2-luciferase virus (a, b) and further pro-
cessed as described for the initial test. On day 4 luciferase activity was measured and
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Figure 3.19: Initial test of the (CAGA)12MLP-luciferase virus and the (BRE)2-luciferase
virus in HSC. HSC were transfected with siRNA on day 1 and infected with either the
(CAGA)12MLP-luciferase virus or the (BRE)2-luciferase virus on day 2. Prior to stimulation
HSC were starved and subsequent stimulated for 8 h with either 1 ng/ml TGF-β1 or 50 ng/ml
BMP-7. Luciferase activity was measured and LCPS per µg protein were calculated.
The test revealed that both constructs are functional. Furthermore, (CAGA)12MLP-luciferase is
specific for TGF-β1 and (BRE)2-luciferase is specific for BMP-7.
the protein concentration of the cell lysates was determined. LCPS (light counts per sec-
ond) per µg protein were calculated and plotted in the graph (y-axis). Infected, but not
stimulated HSC were used as negative controls. HSC transfected with siEng and stimu-
lated with TGF-β1 showed an increased (CAGA)12MLP-luciferase activity (Fig. 3.20 a).
Stimulation with BMP-7 resulted in a marginal change of the (CAGA)12MLP-luciferase
activity. Luciferase activity of unstimulated HSC (negative controls) was almost equal
among HSC transfected with siEng and the corresponding controls. In contrast lu-
ciferase activity of the negative controls of the (BRE)2-luciferase assay (Fig. 3.20 b) re-
sulted in different activities when compared to each other. HSC transfected with siEng
and infected with (BRE)2-luciferase virus forces a strong increase of the basal activity
(Fig. 3.20 b). This means, that transfection of HSC with siEng induced an increase in
the basal activity of the BMP-7 pathway. Untransfected HSC (Con) revealed the same
stimulation pattern, when infected with the (BRE)2-luciferase virus, as HSC transfected
with siCon.
(CAGA)12MLP-luciferase is activated through binding of phosphorylated Smad3.
Therefore, phosphorylation of Smad3 was additionally verified by Western blot analy-
sis (Fig. 3.20 b). HSC were transfected with siRNA on day 2. On day 3 the medium was
renewed with DMEM 10% FCS and again replaced for starvation with DMEM 0.5%
FCS in the late afternoon (approx. 4 p.m.). On day 4 HSC were stimulated for a time
period of 1 h with either 1 ng/ml TGF-β1 or 50 ng/ml BMP-7. HSC were harvested,
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Figure 3.20: The effect of endoglin on Smad activation. Smad3 and Smad1 activation was
analyzed by (a, b) reporter gene assay and (c) by Western blot analysis. HSC were transfected
with siRNA on day 1. For reporter gene assay HSC were additionally infected on day 2 with
either the (CAGA)12MLP-luciferase virus or the (BRE)2-luciferase virus (a, b). Prior to stimula-
tion HSC were starved for 16 h and subsequent stimulated for 8 h with either 1 ng/ml TGF-β1
or 50 ng/ml BMP-7. Luciferase activity was measured (a, b) and LCPS per µg protein were
calculated. (c) HSC were harvested using Ripa complete supplemented with the phophatase
inhibitor cocktail II. For Western blot analysis 20 µg protein were loaded onto a 4-12% Bis-Tris
gel. Antibodies specific for endoglin and phosphorylated Smad1/3 were used. β-Actin was
used as a loading control.
TGF-β1 stimulation resulted in an increase in Smad3 phosphorylation in HSC lacking endoglin.
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protein concentration was determined and 20 µg of cell lysate were loaded onto the gel.
Endoglin expression and phosphorylation of Smad1 and Smad3 were detected using
specific antibodies. Without any stimulation Smad1 and Smad3 were not phospho-
rylated. Upon stimulation with TGF-β1 a marginal increase in pSmad1 and pSmad3
was detected. However, HSC transfected with siEng showed a marginal increase in
phosphorylation of Smad3 compared to the corresponding controls. Stimulation with
BMP-7 resulted in phosphorylation of Smad1. Differences in the phosphorylation pat-
tern of Smad1 between untransfected HSC (Con) and HSC transfected with siEng could
not be detected.
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Chapter 4
Discussion
For a coherent discussion it makes sense to form three sections. The first section dis-
cusses the RNAi approach, as the fundament of this thesis. The second section dis-
cusses the effect of endoglin silencing on hepatic stellate cells, especially under the
aspect of transdifferentiation. In the third section the results of the initial stimulation
experiments are discussed. Finally, the results of the second and third partition will be
compared and discussed.
4.1 Down-regulation of endoglin
To examine the function of endoglin in HSC two kinds of RNAi approaches were es-
tablished. In order to perform in vivo experiments, an adenoviral construct encod-
ing shRNA targeting mouse endoglin was generated, amplified, purified and finally
pretested in COS-7 and HSC. For in vitro experiments siRNA oligonucleotides were
obtained from Qiagen and used to silence endoglin in HSC.
Generation of a functional shRNA virus is more demanding than the use of siRNA
oligonucleotides, because the production of an adenovirus is a challenge of its own.
First of all a homologous recombination of the shuttle vector and the viral backbone
must be achieved. This step was simplified by using the BLOCK-iT Adenoviral RNAi
Expression System, which provides the opportunity to perform the homologous recom-
bination in vitro. Transfection of eucaryotic cells with large plasmids for homologous
recombination is not very efficient. Furthermore, during homologous recombination
and during amplification the insert might be lost by re-arrangements. This results in an
increased number of wild type virus and an decreased number of the intended virus.
Homologous recombination and amplification have been performed in between the
92
4.1. Down-regulation of endoglin
siRNA experiments using COS-7 and HSC. This amplification might explain why the
adenovirus 12.1 is able to silence endoglin in COS-7, but loses its functionality in HSC.
Another reason might be that endoglin is endogenously expressed in HSC while it is
heterologously expressed in COS-7. Therefore, the non-coding sequence of both mRNA
transcripts are different in size and sequence. This forces changes in the three dimen-
sional structure and in the stability of the mRNA and alters the accessibility of the
siRNA/RISC complex to the coding sequences. (siRNAs used in this study target a
sequence within the coding sequence of endoglin)
In order to perform the in vitro experiments, siRNA oligonucleotides were taken into
account. Transfection of HSC using siRNA oligonucleotides and HiPerFect - as trans-
fection reagent - was initially in doubt, because primary HSC are normally very diffi-
cult to transfect. However, first experiments with fluorescence-labelled siRNA yielded
a transfection efficiency of almost 100%. This high transfection efficiency of siRNA
oligonucleotides compared to the very low transfection efficiency of a plasmid might
be due to the size of the transfection complex, which is formed by DNA and transfection
reagent. These complexes are smaller in case of the very short siRNA oligonucleotides.
Furthermore, for a successful plasmid transfection the plasmid must finally reach the
nucleus. In contrast siRNA function is mediated through the Dicer complex, which is
localized within the cytoplasm. Last but not least it was possible to show that down-
regulation of endoglin is due to mRNA degradation and not due to the disturbance of
the transcriptional process. This was proven by Northern blot analysis as well as by
semi-quantitative PCR. Anyway, the transfection efficiency, the knock down efficiency
and the sustained character, which were confirmed in all experiments, provide a stable
basis to characterize HSC lacking endoglin.
To confirm the specificity of the RNAi phenotype, it is important to exclude non-
specific down-regulation of another gene as the inducer of the observed phenotype.
Therefore, other siRNA targeting endoglin were tested regarding their efficiency to
down regulate endoglin. This is an appropriate control, because two different siRNA
are statistically not able to silence the same nonspecific mRNA. However, these siRNA
were not efficient enough to silence endoglin to the same extant as siEng that was used
during this study. Therefore, the confirmation of the specificity of the RNAi phenotype
is still under investigation. Another alternative to confirm the specificity of the siRNA
is to reintroduce the targeted gene. In order to reintroduce endoglin in HSC a virus
overexpressing endoglin is necessary. Due to the fact that the generation of this virus is
very time consuming this experiment is currently ongoing.
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The activation of an interferon (IFN) response, which is caused by the introduction
of dsRNA, could be excluded. An interferon response might lead to nonspecific trans-
lational inhibition, cell cycle arrest, a shutdown of the global protein expression or,
potentially, to apoptosis shortly after transfection [104] [105]. However, modifications
obtained for HSC transfected with siRNA targeting endoglin did not occur shortly after
transfection, instead of this modifications became manifested on day 5 of culture. Fur-
thermore, transfection of HSC with scrambled siRNA (siCon) did not lead to apoptosis
or other obvious changes, e.g. morphological changes, compared to untransfected HSC.
Therefore, modifications obtained on day 5 in HSC transfected with siEng were not due
to an interferon response. Anyway, to further support that an interferon response can
be excluded the activation of IFNs, e.g. type-I interferons, should be determined.
Furthermore, the kinetic of endoglin suppression is in accordance with previous
studies, which show endoglin as a relatively stable glycoprotein with a half-life of ap-
proximately 17 h [112]. In this study endoglin silencing reached a suppression of 50-
70% after 24 h and a suppression of 95-98% after 48 h post siRNA transfection. This
result is comparable with the half life of 17 h obtained in other studies.
Even though the very efficient and sustained character of the knock down approach
is the basis of the following experiments, it also raises a very important question. What
kind of mechanism is responsible for silencing effect for at least 16 days? In order to
exclude apoptosis a TUNEL test was performed. This assay revealed that HSC trans-
fected with siEng were not apoptotic. This was supported by the observation that HSC
were adherent at each time point analyzed. In contrast, floating cells were not detected
at any time point analyzed. Therefore, down-regulation of endoglin is a persistent pro-
cess in viable HSC. This suggests the existence of an autocrine feedback loop, in which
endoglin triggers its own expression. However, to date there are no data published,
which discuss such a feedback loop. Therefore, it might be that this siRNA might
change the DNA methylation pattern within the coding region and, thus, within the
promotor region of endoglin. Such a methylation process, which is induced by siRNA,
within the coding region is not reported yet. However, there is at least one publica-
tion showing that synthetic siRNA, which targets CpG islands, is able to induce DNA
methylation in mammalian cells. This in turn results in an repressed gene expression
at the transcriptional level [109].
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4.2 The impact of endoglin down-regulation on HSC transdif-
ferentiation
As already mentioned it was possible to silence endoglin expression in vitro very ef-
ficiently for more than 17 days using siRNA oligonucleotides. This sustained and ef-
ficient knock down allowed us to analyze HSC transdifferentiation in the absence of
endoglin. To mimic the in vivo transdifferentiation of HSC to MFB, an established in
vitro transdifferentiation model was used. This model is based on the cultivation of
primary HSC on uncoated tissue culture dishes in the presence of a high serum con-
tent (10% FCS) [113]. Under this experimental setting the suppression of endoglin re-
sulted in multiple significant changes, such as a diminished loss of vitamin A as well
as changes in cellular morphology. Both changes stand for an inhibition of transdiffer-
entiation. This inhibition of transdifferentiation could also be induced when HSC were
transfected with siEng at later time points, but before day 5 of initial culture. This indi-
cates that an arrest of transdifferentiation and a partial reversion of cellular activation is
possible in already fully activated HSC. Activation of HSC starts as a result of isolation
and seeding. Consistently, such a phenotypic reversion of activated HSC was recently
demonstrated in precision cut liver slices [114], indicating that HSC once activated have
the potential to redifferentiate into a quiescent phenotype at least in vivo.
Morphological changes, which were observed during transdifferentiation of HSC,
are due to a reprogramming of HSC. This reprogramming is characterized by the acqui-
sition of contractile and migratory properties [115] and is accompanied by an increased
expression of α-SMA [116]. Although significant differences in cellular morphology
were observed, the expression of α-SMA was not altered in cells, in which endoglin
expression was silenced. On the one hand this finding is consistent with previous stud-
ies, in which α-SMA expression was not modified when Smad7 and Smad3 were in-
activated [117] [118]. Smad7 and Smad3 are important key components that affect the
outcome of transdifferentiation. In contrast, a significant reduction of α-SMA expres-
sion in HSC was observed when the activity of profibrogenic cytokines, i.e. PDGF-B
or TGF-β1, was abrogated [119] [120]. On the other hand the experimental setting per-
mits the earliest maximal down-regulation of endoglin on day 3. At this time α-SMA
expression is already initiated. Therefore, it might be too late to influence α-SMA ex-
pression. This is consistent with other studies, which were performed with stem cells.
In stem cells endoglin deficiency inhibits α-SMA expression only before myogenic de-
termination takes place. If endoglin is down-regulated after myogenic determination,
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i.e. when α-SMA is expressed, there was no impact on α-SMA expression [121]. This is
comparable to the results obtained in this thesis.
Although there were no changes in α-SMA expression in endoglin knock down cells
compared to control cells, the organization of the actin cytoskeleton was greatly altered
as initially demonstrated with phalloidin. To describe these alterations, which occurred
in the absence of endoglin, in more detail CRP2-GFP was overexpressed. CRP2 is a
LIM-domain protein and a specific marker for HSC with high affinity for the actin cy-
toskeleton [122]. CRP2-GFP was primarily localized along cytoskeletal fibers in control
cells. However, it was re-localized to short fibres and their termini in the absence of
endoglin. Additionally, an untagged version of CRP2 was overexpressed and F-actin
was again stained with phalloidin. (Due to the strong fluorescence and the limitation
of the filters a double stain of phalloidin and CRP2-GFP could not be performed.) On
the one hand the staining pattern of this last experimental setting showed aspects of
the phalloidin staining pattern and of CRP2-GFP staining pattern. On the other hand
this last experimental setting revealed partially new alterations. Hence it is obvious
that 1) the lack of endoglin forces changes in the organization of the cytoskeleton, 2)
endoglin and CRP2 might interact, because 3) the localization of CRP2 differs when en-
doglin is silenced and 4) overexpression of CRP2 while endoglin is reduced results in a
re-arrangement of the cytoskeleton. Therefore, it is likely that phalloidin directly binds
F-actin while CRP2 binds to F-actin through another protein, which also interacts with
endoglin, e.g. Zyxin. Zyxin is another member of the LIM-domain protein family and
was previously found to interact with CRP2 [123]. It is further known that Zyxin binds
to the C-terminus of endoglin [51]. Moreover, the interaction of Zyxin and endoglin in
endothelial cells was found to be accompanied by a depletion of Zyxin at focal adhe-
sion sites associated with inhibition of cell migration [51]. Therefore, Zyxin might be
the missing link between endoglin, CRP2 and F-actin. If this link between CRP2 and en-
doglin is modified, CRP2 might be relocalized. This in turn may alter the organization
of the cytoskeleton. On the other hand CRP2 is also a LIM-domain protein. Therefore,
it might also be possible that CRP2 directly interacts with endoglin. Another putative
candidate to link CRP2, endoglin and F-actin is ZRP-1 (Zyxin related protein1). ZRP-1
is highly homologous to Zyxin [124] and binds endoglin [52]. Furthermore, endoglin
regulates cytoskeletal organization through binding to ZRP-1 [52] in endothelial cells.
However, the diversity of cytoskeleton alterations can not be explained yet. More in-
formation especially about the interaction of endoglin with CRP2 and Zyxin and other
components are necessary. Anyway, based on these results it is likely that endoglin and
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Zyxin have essential functions in controlling HSC migration and contractility during
transdifferentiation.
In order to investigate the function of endoglin in controlling HSC migration, a
wound healing migration assay was performed. Surprisingly, no differences between
migration of HSC lacking endoglin and the corresponding controls have been observed.
This negative result is either caused by the low density of cells on the spot of HSC mi-
gration or the experimental setting in general is not appropriate. During this thesis
it became obvious that inhibition of transdifferentiation and especially inhibition of
morphological transdifferentiation, which is caused by endoglin down-regulation, de-
pends on cell density. The lower the cell density the less the inhibitory effect, which is
imposed by the absence of endoglin. A scratch and the following migration inevitably
leads to a low number of cells around the scratch itself. Therefore, a migration assay
will be performed, in which the potential of HSC to migrate through a thin layer of col-
lagen I or fibronectin towards a defined stimulus is determined. On the other hand an
inversion assay will be performed in which migration is facilitated by collagen degra-
dation/increased MMP activity. This might be an appropriate experiment, because in
previous studies it was demonstrated that endoglin enhances the invasive character of
tumor cells [125].
Another classical feature of HSC during transdifferentiation is an increase in their
proliferation rate. Due to the fact that the advantages and disadvantages of the 3H-
thymidine and the BrdU proliferation assays are still under discussion both assays
were performed. In both assays HSC transfected with siEng were less proliferative
than the corresponding controls. This modification might be caused by Alk1 and Alk5,
because it was demonstrated in endothelial cells that cellular migration and prolifera-
tion is regulated by a balanced system of two TGF-β receptors, i.e. ALK5 and ALK1
[10]. Here ALK1 mediates migration/proliferation and requires the activation of ALK5
[9]. To date, the function of endoglin as a critical modulator of ALK1 responses is
controversially discussed [23] [47] [126]. On the one hand it was shown that ALK1
promotes profibrogenic actions via induction of Id1 in HSC [127]. On the other hand
it was shown that endoglin promotes antifibrogenic actions by directly antagonizing
ALK5/Smad signaling [9]. In this thesis endoglin deficiency was found to be associated
with reduced cellular proliferation. A reduced proliferation would point towards a de-
crease in ALK1 activity as a profibrogenic component. In line with this the comparative
microarray revealed a reduction in ALK1 expression, whereas ALK5 expression was
unaffected in cells lacking endoglin. This result supports the putative role for ALK1
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in cell proliferation and may present a link between endoglin and ALK1 expression as
well as endoglin and ALK1 function. Again substantiating the idea that endoglin may
control transdifferentiation by promoting the ALK1 pathway. It is currently under in-
vestigation, if the reduced proliferation is due to a decreased ALK1 expression or if it is
an indirect effect of the transdifferentiation arrest.
Based on the presented data it can not be determined whether the observed al-
terations are a consequence of the inhibition of transdifferentiation or whether the
observed alterations are directly caused by endoglin down-regulation and therefore
jointly responsible for the inhibition of transdifferentiation. To directly determine these
interrelations, a detailed analysis of the underlying mechanisms and components has
to be performed in a time dependent manner.
Since it was possible to show a putative role for endoglin in proliferation and, thus,
in the ALK1 pathway, there might also be a putative role for endoglin in the regula-
tion of the ECM expression. An increase in the expression of ECM components is a
further classical feature of HSC during transdifferentiation. In contrast to proliferation
ECM synthesis is regulated by the TGF-β1/ALK5/Smad3 signaling pathway. The TGF-
β1/ALK5/Smad3 signaling pathway is responsible for the transcriptional activation of
ECM components including collagen type I and fibronectin [117] [128] [129]. It has
been shown that overexpression of endoglin inhibits the ALK5/Smad3 pathway and,
therefore, inhibits ECM protein expression [48] [20]. In contrast, experiments in this the-
sis, which were performed with siRNA in the presence of a high serum content (10%
FCS), imply that this pathway might not be affected by endoglin. Western blot analy-
sis revealed a significant decrease of collagen type I, collagen type IV and fibronectin
accumulation in HSC lacking endoglin. A reduced amount of collagen type I was also
detected in the supernatant of HSC treated with siRNA targeting endoglin (data not
shown). In contrary Northern blot analysis as well as microarray analysis did not show
a corresponding down-regulation on the level of mRNA. Thus, changes in the ECM
abundance are not the result of alterations in gene activity, which are normally caused
by alterations in the TGF-β1/ALK5/Smad3 signaling pathway. However, there are two
potential explanations: a reduced translation or an increased degradation. A reduced
translation can be investigated by metabolic labelling. An increased degradation might
be due to an increased MMP activity or a decreased TIMP activity. Therefore, MMP
activity as well as TIMP activity should be investigated.
Endoglin is connected with a variety of different signaling pathways. This was al-
ready shown in former studies [130] and became additionally evident from this study.
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down-regulation of endoglin results in a wide range of cellular alterations, which can
not be explained with alterations of a single pathway or of a single molecular mecha-
nism. To yield more information of the molecular mechanism, which are responsible
for the inhibition of transdifferentiation, a cDNA microarray was performed. Due to
the difficulty to determine a time point, which optimally reflects the observed alter-
ations, the microarray assay was performed on day 8. On day 8 differences in transd-
ifferentiation are obvious and already manifested. With this microarray a huge num-
ber of genes were identified, which were differentially expressed when endoglin was
silenced. Therefore, this microarray opens up new possibilities to explain the obser-
vations that were revealed in the previous experiments. However, the array revealed
that the expression of MMP10 (stromelysin-2), a protein that is involved in matrix pro-
tein degradation, was significantly increased. An increase of MMP10 in turn might
contribute to the degradation of ECM components. This supports the finding that the
decrease of ECM is rather caused by protein degradation than by gene regulation. The
microarray data also revealed changes in gene expression of components of the Wnt
signaling pathway. Members of this protein family are differentially expressed and
regulated during transdifferentiation [131] [132] and determine the potential of HSC
to transdifferentiate [133]. However, the strongest down-regulated gene identified in
this microarray was α2-macroglobulin. α2-Macroglobulin was previously found to be
upregulated in cultured HSC during in vitro transdifferentiation [134] [135]. This fur-
ther supports the finding that endoglin suppression inhibits HSC transdifferentiation.
Nowadays α2-macroglobulin is also discussed as a marker for liver fibrosis [136]. There-
fore, α2-macroglobulin might be beneficial to find a link between these in vitro exper-
iments and the in vivo processes. Additionally, α2-macroglobulin is also known as a
cytokine transporter for IL-8, IL-1, TNF-α and TGF-β and regulates the supply of these
cytokines [137]. To date it is unknown if and how the absence of α2-macroglobulin in
its role as a cytokine transporter influences the transdifferentiation process, but its in-
volvement is most likely. Last but not least the gene classification supports the results,
which were obtained in this thesis, in a global point of view. ”Receptor signaling”
reconfirms the well established function of endoglin as an important receptor for cell
signaling. ”Development” and ”cell differentiation” are appropriate to cover all the ob-
served cell alterations. However, cellular import and export are not investigated yet,
but their investigations might reveal very interesting and informative results.
So far all the experiments were performed with siRNA targeting endoglin. How-
ever, based on the efficient down-regulation of α2-macroglobulin, as a consequence
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of endoglin silencing, α2-macroglobulin was directly down regulated. Direct down-
regulation was evoked using siRNA targeting α2-macroglobulin. In this way it can
be determined a) if α2-macroglobulin functions as a down-stream component of en-
doglin and b) which alterations of the endoglin knock down phenotype is caused by
the lack of α2-macroglobulin. Even though these siα2M experiments just started first
results were already obtained. Bright field microscopy revealed an inhibition of mor-
phological transdifferentiation. These alterations are akin to the observation made with
siRNA targeting endoglin. In contrast ECM abundance seems to be unaffected in HSC
transfected with siα2M. Therefore, it seems that the lack of α2-macroglobulin might be
responsible for at least the morphological alterations observed in siEng experiments.
However, before further experiments can be performed, the specificity of the an-
tibodies need to be confirmed. While the α2-macroglobulin antibody, which is raised
against human, is very weak and difficult to handle, the other α2-macroglobulin anti-
body, which is raised against rat, revealed an unspecific band.
4.3 The role of endoglin in the TGF-β1 and BMP-7 pathways
As mentioned before an established in vitro transdifferentiation model was used to
mimic the in vivo transdifferentiation of HSC to MFB. This model is based on the cul-
tivation of primary HSC on uncoated tissue culture dishes in the presence of a high
serum content (10% FCS) [113]. In this way it was possible to characterize the func-
tion of endoglin during the process of transdifferentiation. However, endoglin binds
several ligands of the TGF-β superfamily and the growth medium contains a broad
range of different ligands. Therefore, the agonist or the agonist spectrum causing the
alterations in the absence of endoglin are unknown. To narrow this range stimulation
experiments were performed using TGF-β and BMP-7, which are key cytokines in liver
fibrosis.
Prior to stimulation experiments the (CAGA)12MLP-luciferase virus and the (BRE)2-
luciferase virus were generated, amplified and tested regarding their functionality and
specificity. (CAGA)12MLP-luciferase is known to be specifically activated by phospho-
rylation of Smad3 [110]. Smad3 phosphorylation in turn is induced by TGF-β1 [138]
[11]. (BRE)2-luciferase in HSC is known to be specifically activated by phosphoryla-
tion of Smad1 [20]. Smad1 phosphorylation in turn is mainly induced by BMP-7 and
only marginally induced by TGF-β1 [20]. Due to the fact that the conversion of par-
ticle to plaque forming units (Pfu) was roughly estimated, the optimal concentration
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of virus was determined using different virus concentrations. The test revealed an op-
timal concentration of 2 · 108 Pfu/ml for (CAGA)12MLP-luciferase virus and an op-
timal concentration of ≥ 3 · 108 Pfu/ml for (BRE)2-luciferase virus. Summarized, it
was demonstrated that both viral constructs are a) highly specific and b) very sensi-
tive to the corresponding cytokine. After the functionality and the specificity of the
(CAGA)12MLP-luciferase virus (BRE)2-luciferase virus had been tested the impact of
endoglin on the TGF-β and the BMP-7 pathways was analyzed by reporter gene assay
and by Western blot analysis.
Western blot analysis revealed an increased Smad3 phosphorylation in HSC stim-
ulated with TGF-β1 (1 µg/ml; 1 h). This was supported by the reporter gene assay,
which revealed an increased Smad3 activity in HSC stimulated with TGF-β1 (1 µg/ml;
6 h). However, phosphorylation of Smad3 in HSC transfected with siEng was stronger
than in the corresponding controls. Furthermore, stimulation with BMP-7 results in a
marginal increase in Smad3 phosphorylation and activity. But compared to the TGF-β1
stimulation the phosphorylation of Smad3 induced by BMP-7 stimulation is marginal
increased in HSC lacking endoglin. These results imply an inhibitory function of en-
doglin towards the TβRII/ALK5/Smad3 pathway. This is consistent with former stud-
ies, which also show an inhibitory function of endoglin towards the TβRII/ALK5/
Smad3 pathway [20].
Phosphorylation and activity of Smad1 are increased upon stimulation with BMP-7
in all samples analyzed. Stimulation with TGF-β1 leads to a marginal increase in Smad1
phosphorylation and activity. Except in the reporter gene assay, where TGF-β1 did not
activate Luciferase expression. In this assay HSC lacking endoglin show a decrease of
Smad1 activity when stimulated with TGF-β1. However, the most important observa-
tion revealed by the BRE-reporter gene assay is a stimulation independent increase of
phosphorylated Smad1 in HSC lacking endoglin. This means that the basal level of
Smad1 activity is increased in HSC transfected with siEng. This in turn points towards
an inhibitory function of endoglin towards the BMP-ligand activated Smad1 pathway.
Finally, stimulation experiments and experiments performed in high serum content
were compared. The results obtained in the presence of a high serum content (10% FCS)
and the results obtained by stimulation experiments seem to be contrary. While stim-
ulation experiments with TGF-β1 revealed an inhibitory function of endoglin towards
the TβRII/ ALK5/Smad3 pathway, the inhibition of transdifferentiation process in high
serum content points towards an activating function of endoglin. However, there was
no link between endoglin and the TβRII/ALK5/Smad3 pathway in experiments, which
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were performed in high serum content.
Due to the fact that integration of many signals form the final output signal, it might
be difficult to transfer the result of a single stimulation experiment to a complex stim-
ulation situation. Experiments performed in the presence of a high serum content are
such a complex stimulation situation. Anyway, it is necessary to perform both kinds of
experiments, because only the entire sum of the single components is able to explain
the whole system.
Last but not least this thesis provides many stable and interesting results regarding
endoglin and its function during HSC transdifferentiation. They are eager for further
investigations.
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Chapter 5
Conclusions
This research was innovative as it is the first to demonstrate that the reduction of en-
doglin expression in HSC causes dramatic changes in profibrogenic functions. These
changes include an inhibition of the morphological transdifferentiation, a reduced pro-
liferation and a decreased abundance of ECM components. Although TGF-β1 is one of
the key regulators of these cellular processes, the present data do not necessarily impli-
cate that these effects are caused by alterations in TGF-β signaling. On the other hand,
an impact of endoglin on ALK1 signaling is obvious, because of the reduced ALK1 ex-
pression. This is further supported by the result of the reporter gene assay showing
a different activation of Smad1 and Smad3 in HSC lacking endoglin. However, these
manifold alterations observed in this study point out an involvement of many signaling
pathways. First evidences are already given by the microarray, supporting an involve-
ment of the WNT pathway. Therefore, it has to be further investigated to which extent
alterations in ALK1 signaling and other signaling pathways (e.g. WNT, BMP) are re-
sponsible for the cellular changes observed in cells lacking endoglin. Additionally, the
functional link between endoglin, CRP2, Zyxin and ZRP-1 needs to be further investi-
gated in order to understand the alterations, which were observed in the organization
of the cytoskeleton. Lastly, this study revealed α2-macroglobulin as another interesting
candidate, which might shape the phenotype of endoglin deficient HSC.
In summary: i) endoglin is essential for the transdifferentiation of HSC in vitro, ii)
transdifferentiation of HSC to MFB in vitro is a process that can be at least partially
reverted, iii) down-regulation of endoglin interferes with expression of ECM compo-
nents, and iv) endoglin is involved in the organization of the cytoskeleton. Based on
these findings, it is apparent that endoglin plays a pivotal role in transdifferentiation
and most likely in hepatic fibrogenesis.
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Selected candidate gene list
Hybridization no. 4 Hybridization no. 2
Name Log Fold P-value Log Fold P-value
(Ratio) Change (Ratio) Change
DV725289 0.69447 4.9 1.07E-08 0.96442 9.2 4.73E-13
Nppc 0.81537 6.5 6.57E-12 0.79672 6.3 0.00004
Edg7 0.48352 3.0 0.00054 0.76781 5.9 0.00012
RGD1306907 predicted 0.65568 4.5 6.85E-09 0.74614 5.6 8.64E-11
Efcbp1 0.35148 2.2 2.00E-01 0.70138 5.0 1.03E-09
Cadps 0.74221 5.5 2.90E-10 0.66915 4.7 8.91E-09
Scn6a 0.58432 3.8 0.00739 0.66287 4.6 0.00298
Chst9 predicted 0.81576 6.5 5.70E-01 0.66052 4.6 1.16E-18
Olr144 0.77432 5.9 0.00004 0.63143 4.3 0.00591
Terc 0.47236 3.0 1.10E-04 0.61150 4.1 7.85E-01
Cxcl2 0.35366 2.3 0.00062 0.57537 3.8 1.52E-07
TC551367 0.51758 3.3 2.69E-06 0.54195 3.5 7.28E-07
Cxxc4 0.42324 2.6 8.82E-04 0.51847 3.3 0.00034
Akr1cl1 predicted 0.53510 3.4 1.15E-06 0.49809 3.1 9.09E-06
Kcnk2 0.45576 2.9 4.17E-04 0.49626 3.1 6.68E-02
AY390379 0.33356 2.2 1.20E-01 0.49443 3.1 9.79E-06
Mmp10 0.36588 2.3 3.30E-02 0.48445 3.1 1.86E-05
Card12 predicted 0.30559 2.0 0.00003 0.47481 3.0 4.17E-05
Omd 0.59851 4.0 4.37E-08 0.47466 3.0 2.99E-05
Ddit4l 0.32350 2.1 0.00001 0.46646 2.9 1.00E-01
TC549300 0.30380 2.0 0.00073 0.44852 2.8 0.00026
Kdr 0.52219 3.3 2.65E-06 0.42203 2.6 6.13E-04
LOC363665 0.55376 3.6 2.67E-12 0.41614 2.6 6.84E-01
Zc3h6 predicted 0.32911 2.1 0.00002 0.40892 2.6 0.00014
Cyp4b1 0.56706 3.7 2.78E-06 0.40744 2.6 1.94E-03
TC565338 0.47773 3.0 8.66E-01 0.40093 2.5 0.00042
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CX570337 0.31343 2.1 3.83E-01 0.39302 2.5 3.67E-03
RGD1559861 predicted 0.32761 2.1 1.98E-01 0.39021 2.5 1.16E-02
Tm4sf1 predicted 0.38123 2.4 6.83E-03 0.38770 2.4 4.65E-03
Sncg 0.42609 2.7 6.86E-04 0.38358 2.4 6.41E-03
ENSRNOT00000021746 0.51314 3.3 1.45E-01 0.37854 2.4 1.72E-02
Slc25a27 0.30872 2.0 0.00004 0.36757 2.3 8.95E-02
Chrne 0.39920 2.5 6.80E-03 0.35050 2.2 0.00015
CF106921 121.117 16.3 7.35E-12 0.34768 2.2 7.32E-02
Cpne7 predicted 0.41668 2.6 1.63E-03 0.34536 2.2 6.81E-02
NCAML1 0.38978 2.5 0.00039 0.34301 2.2 0.00505
Kcnj5 0.32143 2.1 8.32E-01 0.33992 2.2 1.85E-01
RGD1310562 predicted 0.67388 4.7 1.19E-03 0.33789 2.2 1.43E-01
Rgn 0.43950 2.8 3.73E-14 0.33511 2.2 0.00748
LOC362068 0.39186 2.5 2.38E-01 0.31925 2.1 0.00002
Itpka 0.35136 2.2 5.91E-02 0.31790 2.1 7.24E-01
LOC309100 0.31020 2.0 7.36E-01 0.31114 2.0 5.12E-01
Gatm 0.31868 2.1 2.81E-01 0.30251 2.0 7.49E-01
Cox8h 0.45565 2.9 9.31E-05 0.30182 2.0 7.42E-01
NM001013165 -0.33079 -2.1 0.00002 -0.30226 -2.0 0.00005
Slc25a1 -0.32859 -2.1 1.58E-01 -0.30377 -2.0 6.73E-01
Mfap5 predicted -0.34721 -2.2 5.22E-02 -0.30398 -2.0 6.60E-01
Kcnh1 -0.38353 -2.4 6.07E-03 -0.30660 -2.0 0.00002
LOC309816 -0.30956 -2.0 1.32E-04 -0.30961 -2.0 2.95E-05
Foxd4 -0.45426 -2.8 8.11E-14 -0.31043 -2.0 2.65E-05
Icsbp1 predicted -0.32891 -2.1 3.54E-01 -0.31843 -2.1 3.69E-01
Slc7a7 -0.31290 -2.1 0.00108 -0.32212 -2.1 0.00214
LOC294909 -0.33512 -2.2 5.79E-01 -0.32517 -2.1 0.00001
AY539911 -0.32152 -2.1 2.36E-01 -0.32931 -2.1 1.49E-01
Rgs4 -0.41276 -2.6 4.44E-12 -0.32997 -2.1 1.87E-06
RGD1309319 predicted -0.36561 -2.3 8.36E-02 -0.33977 -2.2 3.71E-01
Gp38 -0.34889 -2.2 2.01E-01 -0.34384 -2.2 8.87E-01
Me1 -0.30641 -2.0 5.67E-01 -0.35156 -2.2 3.98E-02
LOC302786 -0.34440 -2.2 6.38E-02 -0.36124 -2.3 2.33E-02
Plekhb1 -0.34566 -2.2 0.00004 -0.36148 -2.3 7.42E-01
LOC289672 -0.32445 -2.1 2.40E-01 -0.36545 -2.3 2.18E-02
Hspcb -0.35765 -2.3 2.70E-03 -0.37442 -2.4 2.53E-09
Ppp1r14c -0.36634 -2.3 1.45E-08 -0.38386 -2.4 5.61E-10
Lcn7 -0.32200 -2.1 2.29E-01 -0.38450 -2.4 5.65E-03
Kctd15 predicted -0.41545 -2.6 0.00002 -0.38716 -2.4 1.14E-02
Apln -0.40953 -2.6 7.76E-12 -0.38752 -2.4 3.10E-10
LOC500109 -0.34314 -2.2 2.42E-01 -0.39377 -2.5 5.70E-03
Garp predicted -0.47514 -3.0 2.91E-04 -0.40411 -2.5 0.00019
Sfrp1 -0.31092 -2.0 4.37E-01 -0.40602 -2.5 1.58E-03
LOC316465 -0.45923 -2.9 2.24E-04 -0.40833 -2.6 3.13E-03
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Gpr43 -0.35553 -2.3 7.83E-02 -0.41090 -2.6 3.65E-03
Arhgdig predicted -0.47284 -3.0 5.19E-02 -0.41472 -2.6 2.73E-03
Acvrl1 -0.45277 -2.8 1.29E-04 -0.42138 -2.6 6.51E-04
NM001014166 -0.37572 -2.4 2.06E-09 -0.42306 -2.6 1.51E-08
Ltbp2 -0.31644 -2.1 3.17E-01 -0.42449 -2.7 7.53E-05
Hspcb -0.42491 -2.7 5.23E-04 -0.43195 -2.7 3.45E-04
Cmklr1 -0.32808 -2.1 3.87E-01 -0.43352 -2.7 2.74E-03
LOC299524 -0.38532 -2.4 5.41E-03 -0.43692 -2.7 2.59E-04
S82649 -0.38045 -2.4 7.16E-03 -0.44214 -2.8 1.89E-04
Rgs5 -0.31305 -2.1 3.88E-01 -0.44968 -2.8 1.23E-04
Mfap4 -0.46464 -2.9 5.76E-05 -0.46318 -2.9 6.57E-05
Bves -0.49166 -3.1 0.00904 -0.46439 -2.9 0.00003
Serpinf1 -0.33688 -2.2 9.52E-02 -0.46725 -2.9 4.46E-05
RGD1307901 predicted -0.33489 -2.2 1.37E-01 -0.46792 -2.9 7.33E-09
RGD1310242 predicted -0.41269 -2.6 3.61E-03 -0.47297 -3.0 2.45E-01
LOC691995 -0.30359 -2.0 6.77E-01 -0.48871 -3.1 1.34E-05
LOC291871 -0.43982 -2.8 2.18E-04 -0.49335 -3.1 1.03E-05
Gprc5b predicted -0.30646 -2.0 0.00053 -0.51119 -3.2 5.10E-02
Nptx2 -0.42928 -2.7 4.08E-04 -0.51175 -3.2 3.73E-06
XM232181 -0.31298 -2.1 0.00584 -0.52019 -3.3 0.00006
Papln predicted -0.33089 -2.1 1.43E-01 -0.52106 -3.3 2.32E-06
Cspg4 -0.47955 -3.0 2.19E-04 -0.52455 -3.3 1.97E-06
RGD1307396 predicted -0.30807 -2.0 7.69E-01 -0.58432 -3.8 1.13E-06
Sfmbt2 predicted -0.62968 -4.3 0.00069 -0.60905 -4.1 0.00695
Tgm2 -0.35177 -2.2 3.93E-02 -0.61434 -4.1 1.90E-08
Prss35 predicted -0.42866 -2.7 2.68E-13 -0.61883 -4.2 9.47E-01
Jph2 -0.34055 -2.2 1.65E-01 -0.62434 -4.2 1.63E-08
AW143823 -0.37713 -2.4 1.65E-09 -0.64010 -4.4 5.73E-19
LOC687266 -0.46682 -2.9 4.05E-04 -0.64181 -4.4 5.89E-04
M22360 -0.73631 -5.4 3.55E-10 -0.66392 -4.6 8.92E-07
Cthrc1 -0.38436 -2.4 5.67E-03 -0.70974 -5.1 2.79E-10
Postn predicted -0.44465 -2.8 2.50E-04 -0.74043 -5.5 1.06E-10
Vil predicted -0.36882 -2.3 3.13E-02 -0.79844 -6.3 1.04E-01
Ptgis -0.44721 -2.8 1.42E-04 -0.88923 -7.7 7.30E-13
Eng -0.54588 -3.5 5.92E-07 -0.92163 -8.3 2.34E-13
M84368 -0.67011 -4.7 1.49E-09 -0.94041 -8.7 1.47E-13
Wisp1 -0.62448 -4.2 1.18E-08 -100.677 -10.2 3.06E-14
A2m -0.75321 -5.7 5.09E-11 -114.377 -13.9 2.08E-15
Table A.1: Selected candidate gene list
This table lists selected genes, which are differentially expressed in both hybridizations (hybridization
no. 2 and no. 4). The complete raw data sets were deposited in the Gene Expression Omnibus (GEO)
repository under accession numbers GSM256740, GSM256756, GSM256757 and GSM256758.
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Vector maps
Vector maps presented in this section are obtained and further modified from either
www.Invitrogen.com or from www.Promega.com. Inserts, which were used for the
shRNA constructs, are presented below.
Endoglin shRNA 12
5-CACCGCACCCTCAGTTGCAACTTAGCGAACTAAGTTGCAACTGAGGGTGC-3
3-GTGGGAGTCAACGTTGAATCGCTTGATTCAACGTTGACTCCCACGAAAA-5
Endoglin shRNA 34
5-CACCGAAAGTCAGGCCTGTGATGGTGCGAACACCATCACAGGCCTGAC-3
3-CTTTCAGTCCGGACACTACCACGCTTGTGGTAGTGTCCGGACTGAAA-5
Endoglin shRNA 56
5-CACCGAATAGATGTACCAGAGTGCAGCGAACTGCACTCTGGTACATCTA-3
3-CTTATCTACATGGTCTCACGTCGCTTGACGTGAGACCATGTAGATAAAA-5
LacZ shRNA
5-CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGTGTAG-3
3-CGATGTGTTTAGTCGCTAAAGCTTTTTAGCGACTAAACACATCAAA-5
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Figure B.9: pAd/Block-itTM-Dest plus (BRE)2-luciferase
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Figure B.10: Empty pGEMT Easy (Promega)
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Figure B.11: pGEMT Easy plus insert
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Figure B.12: Empty pcDNA 3.1(+) (Invitrogen)
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Figure B.14: Empty pGL3 basic vector
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Figure B.15: pGL3 plus (CAGA)12MLP-luciferase
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Figure B.16: pGL3 plus (BRE)2-luciferase
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List of abbreviations
aa amino acid
α2M α2-macroglobulin
α-SMA α-smooth muscle actin
BMP-7 bone morphogenetic protein-7
bp base pair
BSA bovine serum albumin
°C degree Celsius
Col I collagen type I
Col IV collagen type IV
Da dalton
DNA deoxyribonucleic acid
DNase deoxyribonuclease
dsDNA double-stranded DNA
dsRNA double-stranded RNA
E. coli Escherichia coli
Eng endoglin
EtBr ethidium bromide
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Fn fibronectin
g gram
g gravitational force
GFP green fluorescent protein
GFAP glial fibrillary acidic protein
h hour/ hours
HHT1 hereditary hemorrhagic telangiectasia type 1
HSC hepatic stellate cells
HSP70 heat shock protein 70
IgG immunoglobulin G
l liter
LCPS light counts per second
M mole per liter
min minutes
mM milli moles per liter
µ micro (x10−6)
mRNA messenger RNA
n nano (x10−9)
nt nucleotide
OD600 optical density at 600 nm
p pico (x10−12)
PCR polymerase chain reaction
PAGE polyacrylamide gel electrophoresis
Pfu Plaque forming unit
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pH -log[H+]
RNAi RNA interference
rpm revolutions per minute
SDS sodium dodecyl sulfate
shRNA short hairpin RNA
siRNA small interference RNA
ssDNA single stranded DNA
ssRNA single stranded RNA
TGF-β1 transforming growth factor beta 1
U unit of enzyme activity
v volume
V volt
w weight
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